KR101908594B1 - Composition, kit or microarray for indentifying athletic performance comprising marker polynucleotide, and method for obtaining information for indentifying athletic performance using the same - Google Patents
Composition, kit or microarray for indentifying athletic performance comprising marker polynucleotide, and method for obtaining information for indentifying athletic performance using the same Download PDFInfo
- Publication number
- KR101908594B1 KR101908594B1 KR1020160013528A KR20160013528A KR101908594B1 KR 101908594 B1 KR101908594 B1 KR 101908594B1 KR 1020160013528 A KR1020160013528 A KR 1020160013528A KR 20160013528 A KR20160013528 A KR 20160013528A KR 101908594 B1 KR101908594 B1 KR 101908594B1
- Authority
- KR
- South Korea
- Prior art keywords
- polynucleotide
- snp
- marker
- seq
- group
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6834—Enzymatic or biochemical coupling of nucleic acids to a solid phase
- C12Q1/6837—Enzymatic or biochemical coupling of nucleic acids to a solid phase using probe arrays or probe chips
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/124—Animal traits, i.e. production traits, including athletic performance or the like
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Abstract
A composition for identifying exercise performance, comprising a single nucleotide polymorphic marker polynucleotide, a kit, a microarray, a method for obtaining information required for confirming exercise performance using the same, and a computer- And provides a computer-readable medium containing the program.
Description
A composition for identifying exercise performance, comprising a single nucleotide polymorphic marker polynucleotide, a kit, a microarray, a method for obtaining information required for confirming exercise performance using the same, and a computer- Readable medium having recorded thereon a program.
There is a genetic study of the relationship between genetic phenotype and DNA sequence variation. The number of human genes revealed to date is known to be about 20,500, and the most common DNA sequence variation is single nucleotide polymorphism (SNP).
A single nucleotide polymorphism is a common mutation in one of several DNA bases in a single region of a chromosome, with about 3 million single nucleotide polymorphisms present in the human genome, representing about one in every 500 to 1,000 nucleotides. Single nucleotide polymorphisms are highly frequent and stable and distributed throughout the genome, resulting in genetic diversity of individuals.
In humans, the DNA is arranged in 22 autosomes and 2 sex chromosomes, each of at least 34 million (chromosome 21) to a maximum of 263 million The number of SNPs in humans is over 10 million (3.2 billion / 300 bp), reaching a total of 3,195,550 base pairs (bp) It reaches.
In all humans, 99.9% of the nucleotide sequence is the same. There are 10 million SNPs in 0.1 million SNPs, so human differences are biologically different from each other and there are individual differences in exercise performance. Recently, a number of genes related to exercise performance have been proposed (Bray et al., 2009). However, it is very difficult to directly use the genes suggested to be related to the exercise performance proposed in the past for locating sports gifted in Korea or to analyze each human SNP one by one, because it takes a great deal of time and money.
Therefore, it is required to identify single nucleotide polymorphic markers of athletes including Koreans, and to use such markers.
One aspect is to provide a composition for identifying exercise performance comprising a marker polynucleotide.
Another aspect is to provide a kit for confirming exercise performance including a marker polynucleotide.
Another aspect of the present invention is to provide a microarray for confirming the performance of a motion, wherein the marker polynucleotide comprises a substrate immobilized on a surface thereof.
Another aspect is to provide a method of obtaining the information required to confirm exercise performance.
Another aspect is to provide a computer-readable medium containing a computer-executable program for verifying motion performance of an entity.
One aspect is a method for producing a polynucleotide comprising a first polynucleotide having 10 or more contiguous nucleotide sequences comprising a 26 th single nucleotide polymorphic site of the nucleotide sequence of SEQ ID NO: 1 and a complementary polynucleotide A first marker polynucleotide comprising the above polynucleotide;
At least one polynucleotide selected from the group consisting of a second polynucleotide having 10 or more consecutive nucleotide sequences including a 26th single nucleotide polymorphic site of the nucleotide sequence of SEQ ID NO: 2 and a complementary polynucleotide thereof A second marker polynucleotide comprising;
A third polynucleotide having 10 or more consecutive nucleotide sequences including a 26th single nucleotide polymorphic site of the nucleotide sequence of SEQ ID NO: 3 and a complementary polynucleotide thereof, and at least one polynucleotide selected from the group consisting of A third marker polynucleotide;
At least one polynucleotide selected from the group consisting of a fourth polynucleotide having 10 or more consecutive nucleotide sequences including a 26 th single nucleotide polymorphic site of the nucleotide sequence of SEQ ID NO: 4 and a complementary polynucleotide thereof A fourth marker polynucleotide comprising;
At least one polynucleotide selected from the group consisting of a fifth polynucleotide having at least 10 consecutive nucleotide sequences including a single nucleotide polymorphic site of the nucleotide sequence of SEQ ID NO: 5 and a complementary polynucleotide thereof A fifth marker polynucleotide;
At least one polynucleotide selected from the group consisting of a sixth polynucleotide having 10 or more consecutive nucleotide sequences including a 26th single nucleotide polymorphic site of the nucleotide sequence of SEQ ID NO: 6 and a complementary polynucleotide thereof A sixth marker polynucleotide;
At least one polynucleotide selected from the group consisting of a seventh polynucleotide having at least 10 consecutive nucleotide sequences including a single nucleotide polymorphic site of the nucleotide sequence of SEQ ID NO: 7 and a complementary polynucleotide thereof A seventh marker polynucleotide comprising;
An eighth polynucleotide having 10 or more consecutive nucleotide sequences comprising a 26th single nucleotide polymorphic site of the nucleotide sequence of SEQ ID NO: 8 and at least one polynucleotide selected from the group consisting of complementary polynucleotides thereof An eighth marker polynucleotide;
At least one polynucleotide selected from the group consisting of a ninth polynucleotide having at least 10 consecutive nucleotide sequences including a single nucleotide polymorphic site of the nucleotide sequence of SEQ ID NO: 9 and a complementary polynucleotide thereof A ninth marker polynucleotide;
A tenth polynucleotide having 10 or more consecutive nucleotide sequences comprising a 26th single nucleotide polymorphic site of the nucleotide sequence of SEQ ID NO: 10 and at least one polynucleotide selected from the group consisting of complementary polynucleotides thereof A tenth marker polynucleotide comprising;
At least one polynucleotide selected from the group consisting of an eleventh polynucleotide having 10 or more consecutive nucleotide sequences including a 26 th single nucleotide polymorphic site of the nucleotide sequence of SEQ ID NO: 11 and a complementary polynucleotide thereof An eleventh marker polynucleotide;
At least one polynucleotide selected from the group consisting of a twelfth polynucleotide having 10 or more consecutive nucleotide sequences including a 26th single nucleotide polymorphic site of the nucleotide sequence of SEQ ID NO: 12 and a complementary polynucleotide thereof A twelfth marker polynucleotide;
A thirteenth polynucleotide having 10 or more consecutive nucleotide sequences including a 26 th single nucleotide polymorphic site of the nucleotide sequence of SEQ ID NO: 13 and at least one polynucleotide selected from the group consisting of complementary polynucleotides thereof A thirteen marker polynucleotide;
One or more polynucleotides selected from the group consisting of a 14th polynucleotide having 10 or more consecutive nucleotide sequences including a 26th single nucleotide polymorphic site of the nucleotide sequence of SEQ ID NO: 14 and a complementary polynucleotide thereof A 14th marker polynucleotide comprising;
At least one polynucleotide selected from the group consisting of a 15th polynucleotide having 10 or more consecutive nucleotide sequences including a 26th single nucleotide polymorphic site of the nucleotide sequence of SEQ ID NO: 15 and a complementary polynucleotide thereof A 15 marker polynucleotide;
At least one polynucleotide selected from the group consisting of a 16th polynucleotide having 10 or more consecutive nucleotide sequences including a 26th single nucleotide polymorphic site of the nucleotide sequence of SEQ ID NO: 16 and a complementary polynucleotide thereof A 16th marker polynucleotide comprising;
A seventeenth polynucleotide having 10 or more consecutive nucleotide sequences including a 26th single nucleotide polymorphic site of the nucleotide sequence of SEQ ID NO: 17, and a complementary polynucleotide thereof, and at least one polynucleotide selected from the group consisting of A seventeenth marker polynucleotide comprising;
At least one polynucleotide selected from the group consisting of an 18th polynucleotide having 10 or more consecutive nucleotide sequences including a 26th single nucleotide polymorphic site of the nucleotide sequence of SEQ ID NO: 18 and a complementary polynucleotide thereof An 18th marker polynucleotide;
One or more polynucleotides selected from the group consisting of a 19th polynucleotide having 10 or more consecutive nucleotide sequences including a 26th single nucleotide polymorphic site of the nucleotide sequence of SEQ ID NO: 19 and a complementary polynucleotide thereof 19th marker polynucleotide;
At least one polynucleotide selected from the group consisting of a 20th polynucleotide having 10 or more consecutive nucleotide sequences including a 26th single nucleotide polymorphic site of the nucleotide sequence of SEQ ID NO: 20 and a complementary polynucleotide thereof A 20 marker polynucleotide comprising;
A polynucleotide having a nucleotide sequence of SEQ ID NO: 21 and a twenty-first polynucleotide having at least 10 consecutive nucleotide sequences including a single nucleotide polymorphic site of the nucleotide sequence of SEQ ID NO: 21 and at least one polynucleotide selected from the group consisting of complementary polynucleotides thereof A 21st marker polynucleotide;
At least one polynucleotide selected from the group consisting of a 22nd polynucleotide having 10 or more consecutive nucleotide sequences including a 26th single nucleotide polymorphic site of the nucleotide sequence of SEQ ID NO: 22 and a complementary polynucleotide thereof A < / RTI > 22 marker polynucleotide;
A 23rd polynucleotide having 10 or more consecutive nucleotide sequences including a 26th single nucleotide polymorphic site of the nucleotide sequence of SEQ ID NO: 23, and a complementary polynucleotide thereof, and at least one polynucleotide selected from the group consisting of A 23rd marker polynucleotide;
A 24 th polynucleotide having 10 or more consecutive nucleotide sequences including a 26 th single nucleotide polymorphic site of the nucleotide sequence of SEQ ID NO: 24, and a complementary polynucleotide thereof, and at least one polynucleotide selected from the group consisting of A 24th marker polynucleotide;
A 25th polynucleotide having 10 or more consecutive nucleotide sequences including a 26th single nucleotide polymorphic site of the nucleotide sequence of SEQ ID NO: 25, and at least one polynucleotide selected from the group consisting of complementary polynucleotides thereof A 25 marker polynucleotide comprising: < RTI ID = 0.0 >
A 26th polynucleotide having 10 or more consecutive nucleotide sequences including a 26th single nucleotide polymorphic site of the nucleotide sequence of SEQ ID NO: 26, and a complementary polynucleotide thereof, and at least one polynucleotide selected from the group consisting of A 26 marker polynucleotide;
A 27th polynucleotide having 10 or more consecutive nucleotide sequences including a 26th single nucleotide polymorphic site of the nucleotide sequence of SEQ ID NO: 27, and a complementary polynucleotide thereof, and at least one polynucleotide selected from the group consisting of 27 marker polynucleotides;
A 28th polynucleotide having 10 or more consecutive nucleotide sequences comprising a 26th single nucleotide polymorphic site of the nucleotide sequence of SEQ ID NO: 28 and at least one polynucleotide selected from the group consisting of complementary polynucleotides thereof A 28 marker polynucleotide;
One or more polynucleotides selected from the group consisting of a 29th polynucleotide having 10 or more consecutive nucleotide sequences including a 26th single nucleotide polymorphic site of the nucleotide sequence of SEQ ID NO: 29 and a complementary polynucleotide thereof 29 marker polynucleotides;
At least one polynucleotide selected from the group consisting of a 30th polynucleotide having 10 or more consecutive nucleotide sequences including a 26th single nucleotide polymorphic site of the nucleotide sequence of SEQ ID NO: 30 and a complementary polynucleotide thereof A 30 th marker polynucleotide;
A 31st polynucleotide having 10 or more consecutive nucleotide sequences comprising a 26th single nucleotide polymorphic site of the nucleotide sequence of SEQ ID NO: 31, and a complementary polynucleotide thereof, and at least one polynucleotide selected from the group consisting of A 31st marker polynucleotide;
A 32nd polynucleotide having 10 or more consecutive nucleotide sequences comprising a 26th single nucleotide polymorphic site of the nucleotide sequence of SEQ ID NO: 32, and a complementary polynucleotide thereof, and at least one polynucleotide selected from the group consisting of A 32 th marker polynucleotide;
At least one polynucleotide selected from the group consisting of a 33 polynucleotide having 10 or more consecutive nucleotide sequences including a 26-th single nucleotide polymorphic site of the nucleotide sequence of SEQ ID NO: 33 and a complementary polynucleotide thereof 33 marker polynucleotides;
A 34th polynucleotide having 10 or more consecutive nucleotide sequences including a 26th single nucleotide polymorphic site of the nucleotide sequence of SEQ ID NO: 34 and at least one polynucleotide selected from the group consisting of complementary polynucleotides thereof 34 marker polynucleotides;
35 th polynucleotide having 10 or more consecutive nucleotide sequences including a 26 th single nucleotide polymorphic site of the nucleotide sequence of SEQ ID NO: 35 and at least one polynucleotide selected from the group consisting of complementary polynucleotides thereof 35 marker polynucleotides;
At least one polynucleotide selected from the group consisting of a 36th polynucleotide having 10 or more consecutive nucleotide sequences including a 26th single nucleotide polymorphic site of the nucleotide sequence of SEQ ID NO: 36 and a complementary polynucleotide thereof 36 marker polynucleotides;
A 37th polynucleotide having 10 or more consecutive nucleotide sequences including a 26th single nucleotide polymorphic site of the nucleotide sequence of SEQ ID NO: 37, and a complementary polynucleotide thereof, and at least one polynucleotide selected from the group consisting of 37 marker polynucleotides;
At least one polynucleotide selected from the group consisting of a 38 polynucleotide having 10 or more consecutive nucleotide sequences including a 26 th single nucleotide polymorphic site of the nucleotide sequence of SEQ ID NO: 38 and a complementary polynucleotide thereof A < / RTI > 38 marker polynucleotide;
39 polynucleotides having 10 or more consecutive nucleotide sequences comprising a 26 < th > first single nucleotide polymorphic site of the nucleotide sequence of SEQ ID NO: 39 and at least one polynucleotide selected from the group consisting of complementary polynucleotides thereof A < / RTI > 39 marker polynucleotide;
One or more polynucleotides selected from the group consisting of a 40 polynucleotide having 10 or more consecutive nucleotide sequences including a 26 th single nucleotide polymorphic site of the nucleotide sequence of SEQ ID NO: 40 and a complementary polynucleotide thereof A < / RTI > 40 marker polynucleotide;
At least one polynucleotide selected from the group consisting of a 41st polynucleotide having 10 or more consecutive nucleotide sequences including a 26th single nucleotide polymorphic site of the nucleotide sequence of SEQ ID NO: 41 and a complementary polynucleotide thereof A 31st marker polynucleotide;
At least one polynucleotide selected from the group consisting of a 42 polynucleotide having 10 or more consecutive nucleotide sequences including a 26 th single nucleotide polymorphic site of the nucleotide sequence of SEQ ID NO: 42 and a complementary polynucleotide thereof A 32 th marker polynucleotide;
A polynucleotide selected from the group consisting of a 43 polynucleotide having 10 or more consecutive nucleotide sequences including a single nucleotide polymorphic site of the nucleotide sequence of SEQ ID NO: 43 and a complementary polynucleotide thereof; 33 marker polynucleotides;
A 44th polynucleotide having 10 or more consecutive nucleotide sequences including a 26th single nucleotide polymorphic site of the nucleotide sequence of SEQ ID NO: 44, and a complementary polynucleotide thereof, and at least one polynucleotide selected from the group consisting of 34 marker polynucleotides;
A 45th polynucleotide having 10 or more consecutive nucleotide sequences including a 26th single nucleotide polymorphic site of the nucleotide sequence of SEQ ID NO: 45 and a complementary polynucleotide thereof; and at least one polynucleotide selected from the group consisting of 35 marker polynucleotides;
One or more polynucleotides selected from the group consisting of a 46th polynucleotide having 10 or more consecutive nucleotide sequences including a 26th single nucleotide polymorphic site of the nucleotide sequence of SEQ ID NO: 46 and a complementary polynucleotide thereof 36 marker polynucleotides;
A 47th polynucleotide having 10 or more consecutive nucleotide sequences comprising a 26th single nucleotide polymorphic site of the nucleotide sequence of SEQ ID NO: 47, and a complementary polynucleotide thereof, and at least one polynucleotide selected from the group consisting of 37 marker polynucleotides;
One or more polynucleotides selected from the group consisting of a 48 polynucleotide having 10 or more consecutive nucleotide sequences including a 26 th single nucleotide polymorphic site of the nucleotide sequence of SEQ ID NO: 48 and a complementary polynucleotide thereof A < / RTI > 38 marker polynucleotide;
One or more polynucleotides selected from the group consisting of a 49th polynucleotide having 10 or more consecutive nucleotide sequences including a 26th single nucleotide polymorphic site of the nucleotide sequence of SEQ ID NO: 49 and a complementary polynucleotide thereof A < / RTI > 39 marker polynucleotide;
One or more polynucleotides selected from the group consisting of a 50 polynucleotide having 10 or more consecutive nucleotide sequences including a 26 th single nucleotide polymorphic site of the nucleotide sequence of SEQ ID NO: 50 and a complementary polynucleotide thereof A < / RTI > 40 marker polynucleotide;
A polynucleotide of the 51st polynucleotide having 10 or more consecutive nucleotide sequences including a 26th single nucleotide polymorphic site of the nucleotide sequence of SEQ ID NO: 51 and a complementary polynucleotide thereof; A 51st marker polynucleotide;
52 polynucleotides having at least 10 consecutive nucleotide sequences comprising the 26 th single nucleotide polymorphic site of the nucleotide sequence of SEQ ID NO: 52 and complementary polynucleotides thereof, and at least one polynucleotide selected from the group consisting of complementary polynucleotides thereof A < / RTI > 52 marker polynucleotide;
53 polynucleotides having 10 or more consecutive nucleotide sequences comprising a 26-th single nucleotide polymorphic site of the nucleotide sequence of SEQ ID NO: 53, and complementary polynucleotides thereof, and at least one polynucleotide selected from the group consisting of A < / RTI > 53 marker polynucleotide;
54 polynucleotides having 10 or more consecutive nucleotide sequences comprising a 26-th single nucleotide polymorphic site of the nucleotide sequence of SEQ ID NO: 54 and at least one polynucleotide selected from the group consisting of complementary polynucleotides thereof 54 marker polynucleotides;
55 polynucleotides having 10 or more consecutive nucleotide sequences including a 26 th single nucleotide polymorphic site of the nucleotide sequence of SEQ ID NO: 55, and complementary polynucleotides thereof, and at least one polynucleotide selected from the group consisting of A < / RTI > 55 marker polynucleotide;
A 56th polynucleotide having 10 or more consecutive nucleotide sequences including a 26th single nucleotide polymorphic site of the nucleotide sequence of SEQ ID NO: 56, and a complementary polynucleotide thereof, and at least one polynucleotide selected from the group consisting of A < / RTI > 56 marker polynucleotide;
57 polynucleotides having at least 10 consecutive nucleotide sequences comprising a 26 th single nucleotide polymorphic site of the nucleotide sequence of SEQ ID NO: 57 and at least one polynucleotide selected from the group consisting of complementary polynucleotides thereof A < RTI ID = 0.0 > 57 < / RTI > marker polynucleotide;
One or more polynucleotides selected from the group consisting of a polynucleotide of the 58th polynucleotide having 10 or more consecutive nucleotide sequences including the 26th single nucleotide polymorphic site of the nucleotide sequence of SEQ ID NO: 58 and complementary polynucleotides thereof A < / RTI > 58 marker polynucleotide;
59 polynucleotides having at least 10 consecutive nucleotide sequences comprising the 26 th single nucleotide polymorphic site of the nucleotide sequence of SEQ ID NO: 59 and at least one polynucleotide selected from the group consisting of complementary polynucleotides thereof A < / RTI > 59 marker polynucleotide;
One or more polynucleotides selected from the group consisting of a 60 polynucleotide having 10 or more consecutive nucleotide sequences including a 26 th single nucleotide polymorphic site of the nucleotide sequence of SEQ ID NO: 60 and a complementary polynucleotide thereof A < / RTI > 60 marker polynucleotide;
One or more polynucleotides selected from the group consisting of a 61st polynucleotide having 10 or more consecutive nucleotide sequences including a 26th single nucleotide polymorphic site of the nucleotide sequence of SEQ ID NO: 61 and a complementary polynucleotide thereof A 61st marker polynucleotide;
62 polynucleotides having at least 10 consecutive nucleotide sequences comprising a 26 th single nucleotide polymorphic site of the nucleotide sequence of SEQ ID NO: 62 and at least one polynucleotide selected from the group consisting of complementary polynucleotides thereof A < / RTI > 62 marker polynucleotide;
One or more polynucleotides selected from the group consisting of a 63 polynucleotide having 10 or more consecutive nucleotide sequences including a 26 th single nucleotide polymorphic site of the nucleotide sequence of SEQ ID NO: 63 and a complementary polynucleotide thereof A < / RTI > 63 marker polynucleotide;
One or more polynucleotides selected from the group consisting of the 64th polynucleotide having 10 or more consecutive nucleotide sequences including the 26th single nucleotide polymorphic site of the nucleotide sequence of SEQ ID NO: 64 and its complementary polynucleotide A 64th marker polynucleotide comprising;
One or more polynucleotides selected from the group consisting of a polynucleotide of the 65th polynucleotide having 10 or more consecutive nucleotide sequences including a 26th single nucleotide polymorphic site of the nucleotide sequence of SEQ ID NO: 65 and a complementary polynucleotide thereof A < / RTI > 65 marker polynucleotide;
One or more polynucleotides selected from the group consisting of a 66 polynucleotide having 10 or more consecutive nucleotide sequences including a 26 th single nucleotide polymorphic site of the nucleotide sequence of SEQ ID NO: 66 and a complementary polynucleotide thereof A < / RTI > 66 marker polynucleotide;
At least one polynucleotide selected from the group consisting of a 67th polynucleotide having 10 or more consecutive nucleotide sequences including a 26th single nucleotide polymorphic site of the nucleotide sequence of SEQ ID NO: 67 and a complementary polynucleotide thereof A < RTI ID = 0.0 > 67 < / RTI > marker polynucleotide;
One or more polynucleotides selected from the group consisting of a 68 polynucleotide having 10 or more consecutive nucleotide sequences comprising the 26 th single nucleotide polymorphic site of the nucleotide sequence of SEQ ID NO: 68 and a complementary polynucleotide thereof A < / RTI > 68 marker polynucleotide;
A 69th polynucleotide having 10 or more consecutive nucleotide sequences including a 26th single nucleotide polymorphic site of the nucleotide sequence of SEQ ID NO: 69, and a complementary polynucleotide thereof, and at least one polynucleotide selected from the group consisting of A < / RTI > 69 marker polynucleotide;
One or more polynucleotides selected from the group consisting of a 70 polynucleotide having 10 or more consecutive nucleotide sequences including a 26 th single nucleotide polymorphic site of the nucleotide sequence of SEQ ID NO: 70 and a complementary polynucleotide thereof A < / RTI > 70 marker polynucleotide;
A 71st polynucleotide having 10 or more consecutive nucleotide sequences comprising a 26th single nucleotide polymorphic site of the nucleotide sequence of SEQ ID NO: 71 and at least one polynucleotide selected from the group consisting of complementary polynucleotides thereof 71 marker polynucleotides;
A 72nd polynucleotide having 10 or more consecutive nucleotide sequences including a 26th single nucleotide polymorphic site of the nucleotide sequence of SEQ ID NO: 72 and at least one polynucleotide selected from the group consisting of complementary polynucleotides thereof A < / RTI > 72 marker polynucleotide;
73 polynucleotides having at least 10 consecutive nucleotide sequences comprising the 26 th single nucleotide polymorphic site of the nucleotide sequence of SEQ ID NO: 73 and at least one polynucleotide selected from the group consisting of complementary polynucleotides thereof A < / RTI > 73 marker polynucleotide;
One or more polynucleotides selected from the group consisting of a 74 polynucleotide having 10 or more consecutive nucleotide sequences including a 26 th single nucleotide polymorphic site of the nucleotide sequence of SEQ ID NO: 74 and a complementary polynucleotide thereof A < / RTI > 74 marker polynucleotide;
75 polynucleotides having at least 10 consecutive nucleotide sequences comprising the 26 th single nucleotide polymorphic site of the nucleotide sequence of SEQ ID NO: 75 and at least one polynucleotide selected from the group consisting of complementary polynucleotides thereof A < / RTI > 75 marker polynucleotide;
One or more polynucleotides selected from the group consisting of a 76 polynucleotide having 10 or more consecutive nucleotide sequences including a 26 th single nucleotide polymorphic site of the nucleotide sequence of SEQ ID NO: 76 and a complementary polynucleotide thereof A < / RTI > 76 marker polynucleotide;
77 polynucleotides having at least 10 consecutive nucleotide sequences comprising the 26 th single nucleotide polymorphic site of the nucleotide sequence of SEQ ID NO: 77 and at least one polynucleotide selected from the group consisting of complementary polynucleotides thereof A < / RTI > 77 marker polynucleotide;
78 polynucleotides having at least 10 consecutive nucleotide sequences comprising the 26 th single nucleotide polymorphic site of the nucleotide sequence of SEQ ID NO: 78 and at least one polynucleotide selected from the group consisting of complementary polynucleotides thereof A < / RTI > 78 marker polynucleotide;
79 polynucleotides having at least 10 consecutive nucleotide sequences comprising the 26 th single nucleotide polymorphic site of the nucleotide sequence of SEQ ID NO: 79 and at least one polynucleotide selected from the group consisting of complementary polynucleotides thereof An < RTI ID = 0.0 > 79 < / RTI > marker polynucleotide;
One or more polynucleotides selected from the group consisting of an 80 polynucleotide having 10 or more consecutive nucleotide sequences including a 26 th single nucleotide polymorphic site of the nucleotide sequence of SEQ ID NO: 80 and a complementary polynucleotide thereof An 80th marker polynucleotide;
An 81 polynucleotide having 10 or more consecutive nucleotide sequences including a 26 th single nucleotide polymorphic site of the nucleotide sequence of SEQ ID NO: 81, and at least one polynucleotide selected from the group consisting of complementary polynucleotides thereof An 81st marker polynucleotide;
One or more polynucleotides selected from the group consisting of a polynucleotide of SEQ ID NO: 82 and a polynucleotide complementary thereto having at least 10 consecutive nucleotide sequences including a 26-th single nucleotide polymorphic site of the nucleotide sequence of SEQ ID NO: 82 An 82 marker polynucleotide;
One or more polynucleotides selected from the group consisting of an 83 polynucleotide having 10 or more consecutive nucleotide sequences including a 26-th single nucleotide polymorphic site of the nucleotide sequence of SEQ ID NO: 83 and a complementary polynucleotide thereof An 83 marker polynucleotide;
One or more polynucleotides selected from the group consisting of 84 polynucleotides having 10 or more consecutive nucleotide sequences including the 26 th single nucleotide polymorphic site of the nucleotide sequence of SEQ ID NO: 84 and complementary polynucleotides thereof An 84 marker polynucleotide;
One or more polynucleotides selected from the group consisting of a polynucleotide of the 85th polynucleotide having 10 or more consecutive nucleotide sequences including a single nucleotide polymorphic site of the nucleotide sequence of SEQ ID NO: 85 and a complementary polynucleotide thereof An 85th marker polynucleotide;
One or more polynucleotides selected from the group consisting of an 86 polynucleotide having 10 or more consecutive nucleotide sequences including a 26 th single nucleotide polymorphic site of the nucleotide sequence of SEQ ID NO: 86 and a complementary polynucleotide thereof An 86 marker polynucleotide;
87 polynucleotide having 10 or more consecutive nucleotide sequences including a 26-th single nucleotide polymorphic site of the nucleotide sequence of SEQ ID NO: 87 and at least one polynucleotide selected from the group consisting of complementary polynucleotides thereof An 87th marker polynucleotide;
One or more polynucleotides selected from the group consisting of the 88th polynucleotide having 10 or more consecutive nucleotide sequences including the 26th single nucleotide polymorphic site of the nucleotide sequence of SEQ ID NO: 88 and its complementary polynucleotide An 88th marker polynucleotide;
89 polynucleotide having 10 or more consecutive nucleotide sequences including a 26-th single nucleotide polymorphic site of the nucleotide sequence of SEQ ID NO: 89, and a complementary polynucleotide thereof, and at least one polynucleotide selected from the group consisting of 89 marker polynucleotide;
A 90th polynucleotide having 10 or more consecutive nucleotide sequences comprising a 26th single nucleotide polymorphic site of the nucleotide sequence of SEQ ID NO: 90, and a complementary polynucleotide thereof, and at least one polynucleotide selected from the group consisting of A < / RTI > 90 marker polynucleotide;
91 polynucleotide having 10 or more consecutive nucleotide sequences including a 26-th single nucleotide polymorphic site of the nucleotide sequence of SEQ ID NO: 91, and complementary polynucleotides thereof, and at least one polynucleotide selected from the group consisting of A < / RTI > 91 marker polynucleotide;
One or more polynucleotides selected from the group consisting of a 92 polynucleotide having 10 or more consecutive nucleotide sequences including a 26 th single nucleotide polymorphic site of the nucleotide sequence of SEQ ID NO: 92 and a complementary polynucleotide thereof A < / RTI > 92 marker polynucleotide;
One or more polynucleotides selected from the group consisting of a 93 polynucleotide having 10 or more consecutive nucleotide sequences including a 26-th single nucleotide polymorphic site of the nucleotide sequence of SEQ ID NO: 93 and a complementary polynucleotide thereof A < / RTI > 93 marker polynucleotide;
A 94th polynucleotide having 10 or more consecutive nucleotide sequences comprising a 26th single nucleotide polymorphic site of the nucleotide sequence of SEQ ID NO: 94, and a complementary polynucleotide thereof, and at least one polynucleotide selected from the group consisting of A < / RTI > 94 marker polynucleotide;
A 95th polynucleotide having 10 or more consecutive nucleotide sequences including a 26th single nucleotide polymorphic site of the nucleotide sequence of SEQ ID NO: 95 and at least one polynucleotide selected from the group consisting of complementary polynucleotides thereof A 95th marker polynucleotide;
A 96th polynucleotide having 10 or more consecutive nucleotide sequences comprising a 26th single nucleotide polymorphic site of the nucleotide sequence of SEQ ID NO: 96, and a complementary polynucleotide thereof, and at least one polynucleotide selected from the group consisting of A 96 marker polynucleotide;
A 97th polynucleotide having 10 or more consecutive nucleotide sequences including a 26th single nucleotide polymorphic site of the nucleotide sequence of SEQ ID NO: 97 and at least one polynucleotide selected from the group consisting of complementary polynucleotides thereof A 97 marker polynucleotide;
A 98th polynucleotide having 10 or more consecutive nucleotide sequences comprising a 26th single nucleotide polymorphic site of the nucleotide sequence of SEQ ID NO: 98 and at least one polynucleotide selected from the group consisting of complementary polynucleotides thereof A < / RTI > 98 marker polynucleotide;
A 99th polynucleotide having 10 or more consecutive nucleotide sequences comprising a 26th single nucleotide polymorphic site of the nucleotide sequence of SEQ ID NO: 99 and at least one polynucleotide selected from the group consisting of complementary polynucleotides thereof A 99th marker polynucleotide;
100 polynucleotides having at least 10 consecutive nucleotide sequences comprising a 26 th single nucleotide polymorphic site of the nucleotide sequence of SEQ ID NO: 100 and at least one polynucleotide selected from the group consisting of complementary polynucleotides thereof A < / RTI > 100 marker polynucleotide;
101 polynucleotide having 10 or more consecutive nucleotide sequences including a 26-th single nucleotide polymorphic site of the nucleotide sequence of SEQ ID NO: 101, and a complementary polynucleotide thereof, and at least one polynucleotide selected from the group consisting of A < / RTI > 101 marker polynucleotide;
One or more polynucleotides selected from the group consisting of a polynucleotide 102 having at least 10 consecutive nucleotide sequences including a single nucleotide polymorphic site of the nucleotide sequence of SEQ ID NO: 102 and complementary polynucleotides thereof A < / RTI > 102 marker polynucleotide;
At least one polynucleotide selected from the group consisting of a 103 polynucleotide having 10 or more consecutive nucleotide sequences including a 26-th single nucleotide polymorphic site of the nucleotide sequence of SEQ ID NO: 103 and a complementary polynucleotide thereof A < / RTI > 103 marker polynucleotide;
A 104th polynucleotide having 10 or more consecutive nucleotide sequences including a 26th single nucleotide polymorphic site of the nucleotide sequence of SEQ ID NO: 104, and a complementary polynucleotide thereof, and at least one polynucleotide selected from the group consisting of A 104th marker polynucleotide;
105 polynucleotide having 10 or more consecutive nucleotide sequences including a 26-th single nucleotide polymorphic site of the nucleotide sequence of SEQ ID NO: 105 and at least one polynucleotide selected from the group consisting of complementary polynucleotides thereof A < / RTI > 105 marker polynucleotide;
A 106th polynucleotide having 10 or more consecutive nucleotide sequences comprising a 26th single nucleotide polymorphic site of the nucleotide sequence of SEQ ID NO: 106 and at least one polynucleotide selected from the group consisting of complementary polynucleotides thereof A < / RTI > 106 marker polynucleotide;
107 polynucleotides having 10 or more consecutive nucleotide sequences comprising a 26-th single nucleotide polymorphic site of the nucleotide sequence of SEQ ID NO: 107 and complementary polynucleotides thereof, and at least one polynucleotide selected from the group consisting of SEQ ID NO: A < / RTI > 107 marker polynucleotide;
108 polynucleotides having at least 10 consecutive nucleotide sequences comprising a single nucleotide polymorphic site of the nucleotide sequence of SEQ ID NO: 108 and at least one polynucleotide selected from the group consisting of complementary polynucleotides thereof 108 marker polynucleotide;
A 109th polynucleotide having 10 or more consecutive nucleotide sequences comprising a 26th single nucleotide polymorphic site of the nucleotide sequence of SEQ ID NO: 109, and a complementary polynucleotide thereof, and at least one polynucleotide selected from the group consisting of 109 marker polynucleotides comprising: < RTI ID = 0.0 >
110 polynucleotides having 10 or more consecutive nucleotide sequences comprising a 26-th single nucleotide polymorphic site of the nucleotide sequence of SEQ ID NO: 110 and at least one polynucleotide selected from the group consisting of complementary polynucleotides thereof A 110th marker polynucleotide comprising;
At least one polynucleotide selected from the group consisting of a 111 polynucleotide having 10 or more consecutive nucleotide sequences including a 26 th single nucleotide polymorphic site of the nucleotide sequence of SEQ ID NO: 111 and a complementary polynucleotide thereof A < RTI ID = 0.0 > 111 < / RTI > marker polynucleotide;
One or more polynucleotides selected from the group consisting of a 112 polynucleotide having 10 or more consecutive nucleotide sequences including a 26 th single nucleotide polymorphic site of the nucleotide sequence of SEQ ID NO: 112 and a complementary polynucleotide thereof A < / RTI > 112 marker polynucleotide;
113 polynucleotides having at least 10 consecutive nucleotide sequences comprising the 26 th single nucleotide polymorphic site of the nucleotide sequence of SEQ ID NO: 113 and at least one polynucleotide selected from the group consisting of complementary polynucleotides thereof A < RTI ID = 0.0 > 113 < / RTI > marker polynucleotide;
One or more polynucleotides selected from the group consisting of the 114th polynucleotide having 10 or more consecutive nucleotide sequences including the 26th single nucleotide polymorphic site of the nucleotide sequence of SEQ ID NO: 114 and its complementary polynucleotide A < / RTI > 114 marker polynucleotide;
At least one polynucleotide selected from the group consisting of a polynucleotide at position 115 having at least 10 consecutive nucleotide sequences including a single nucleotide polymorphic site of the nucleotide sequence of SEQ ID NO: 115 and a complementary polynucleotide thereof Wherein the polynucleotide comprises at least one marker polynucleotide selected from the group consisting of:
In such a composition, it may be included as a set of marker polypeptides comprising a plurality of marker polypeptides. For example, the first set may comprise the first to the 54th marker polypeptides, the second set may comprise the 55th to 69th marker polypeptides, and the third set may comprise the 70th to 115th marker polypeptides, Marker polypeptide. Thus, for example, a composition according to one embodiment may comprise a set of one or more marker polynucleotides selected from the group consisting of a first set, a second set, and a third set.
In such a composition, the exercise performance may be cardiopulmonary function, muscle power (e.g., maximum muscle strength), speed, or a combination thereof. Cardiopulmonary function may be cardiovascular endurance. In the above composition, " for confirming an athletic performance " may be to confirm an excellent degree of cardiorespiratory function and / or muscular strength. The muscle strength may be a maximum muscular strength. The excellent degree may be a degree of the exercise performance of the non-athlete or the athlete, which is greater than the average exercise performance of the person. The greater degree is a statistically significant level, for example, 5%, 10%, 15%, 20%, 25%, 50%, 100%, 200%, 300% or 1000 % ≪ / RTI > By using this criterion, individuals with excellent exercise performance can be selected from the individuals. The athlete may be an elite athlete. The elite athlete may be an athlete who achieves a level of 100%, 200%, 300% or 1000% statistically higher than the average cardiopulmonary endurance strength and / or speed of a person in terms of cardiopulmonary endurance strength and / have. Cardiopulmonary endurance can be identified by measuring heart rate, maximum heart rate or maximum oxygen uptake. The maximum heart rate is the number of times the heart can run the fastest during maximum effort. The maximum oxygen uptake is the maximum energy obtained by aerobic energy metabolism per unit time at the limit of aerobic capacity, which means the maximum amount of oxygen that the human body can use for energy production. Measurement of the maximum oxygen uptake and / or the maximum heart rate may be performed through a maximal test (All-out test). The maximum exercise load test may be to measure the maximum oxygen uptake and / or the maximum heart rate by incrementally increasing the load until the testee's physical strength is completely drained. Muscle strength can be measured and measured by a spring-loaded, strain-gauged, cable-tensioned, or hydraulic-type muscle strength meter, such as a spaded spring type.
The first to 115th marker polynucleotides may have a length of 10 to 51 nt, 11 to 50 nt, 17 to 50 nt, 21 to 50 nt, 31 to 50 nt, or 40 to 50 nt.
The composition for verifying exercise performance may comprise one or more marker polynucleotides, for example, 2, 5, 10, 15, 20, 25, or 54 marker polynucleotides . The composition for confirming exercise performance may include 2 to 115, 5 to 115, and 10 to 115 marker polynucleotides.
In the composition for identifying exercise performance, the marker polynucleotide may be a single polynucleotide or a set of polynucleotides.
In the composition for confirming exercise performance, the marker polynucleotide may further include a sequence complementary to each target nucleic acid at the 5 'end and the 3' end. The sequence complementary to the target nucleic acid may be naturally occurring in the individual or complementary to the sequence introduced in the process of isolating or amplifying the target nucleic acid from the individual.
Wherein each marker polynucleotide has a length from the 5 'terminal nucleotide to the single nucleotide polymorphic site entire nucleotide of 8 to 50 nt, and the length from the nucleotide next to the single nucleotide polymorphism site to the 3' terminal nucleotide is 5 To 50 nt. Each marker polynucleotide may have a length of 5 to 25 nt, such as 10 to 25 nt, 15 to 25 nt, or 20 to 25 nt, from the 5 'terminal nucleotide to the single nucleotide polymorphic site pre-nucleotide. In addition, the length from the nucleotide following the single nucleotide polymorphic site to the 3 'terminal nucleotide may be 5 to 25 nt, such as 10 to 25 nt, 15 to 25 nt, or 20 to 25 nt.
(major / minor)
(major / minor)
(major / minor)
In Tables 1 to 3, the rs number is the number of the SNP registered in the NCBI (http://www.ncbi.nlm.nih.gov, National Center for Biotechnology Information) Genbank, and the sequence shown in the above SEQ ID NO: ≪ / RTI > Those skilled in the art will readily be able to ascertain the location and sequence of the SNP with reference to the rs number.
The column "p-value" in Tables 1 to 3 indicates that the distribution of the genotypes of the SNPs is significantly different from the major allele or minor allele in a given model in athletes and the general population - can mean value.
In the composition for confirming exercise performance, the first to 115th marker polynucleotides may be those having a minor allele or major allele shown in Tables 1 to 3 at a single base polymorphism site. In addition, in the composition for confirming exercise performance, each marker polynucleotide in the first marker polynucleotide to the 115th marker polynucleotide may be a polynucleotide of the corresponding number in which the nucleotide of the single base polymorphism is A, T, G, And a set of eight polynucleotides of complementary polynucleotides thereof. That is, each marker polynucleotide may further include not only the minor allele and the major allele but also the remaining two of the four nucleotides in the nucleotide of the single nucleotide polymorphism site.
Each of the markers in Tables 1 to 3 corresponds to the nucleotide sequence of SEQ ID NOS: 1-115 in sequence as shown in Table 4.
In such a composition, at least two marker polynucleotides of the first to 115th marker polynucleotides may be markers that are linkage disequilibrium to each other.
Linkage disequilibrium (LD) means that certain complexes of alleles or marker polynucleotides are constantly co-inherited at two or more different SNP sites of a given chromosomal region. Thus, if a SNP is in a linkage disequilibrium with other SNPs, the particular allele of the first SNP can often identify alleles in these SNPs that are within the linkage disequilibrium. Linkage disequilibrium is generally due to physical proximity to two loci along the chromosome. An " association disequilibrium segment " may refer to a genomic region comprising multiple SNPs located close to each other and delivered to a block.
The first to 54 marker polynucleotides may be associated with cardiopulmonary function of an individual. Also, the 55th to 69th marker polynucleotides may be associated with muscle strength of the individual. The 70th to 115th marker polynucleotides may also be associated with an individual's speed. Thus, by confirming the allele at the SNP site in these marker polynucleotides, the ability of the individual to perform an exercise can be predicted or confirmed.
In the composition for confirming the exercise performance, each marker polynucleotide may be a primer or a probe. The probe may be one with a detectable label attached thereto. The detectable label may be a known one. The detectable label may be, for example, optical, electrical, or enzymatic. The optical label may be fluorescent, phosphorescent, radioactive, or a combination thereof. The enzymatic label may be one that converts a substrate to a detectable label, e.g., a material that generates an optical or electrical signal, by the action of an enzyme.
A " primer " may be a single-stranded polynucleotide that can act as a starting point in the polymerization of a nucleotide by a polymerase. For example, the primer can serve as a starting point for template-directed DNA synthesis in the presence of suitable conditions, i.e., four different nucleoside triphosphates and polymerases, at the appropriate temperature and in the appropriate buffer Lt; RTI ID = 0.0 > polynucleotides < / RTI > The appropriate length of the primer may vary depending on various factors, for example, temperature and use of the primer. The primer may be 15 to 30 nucleotides in length. In general, the shorter the length of the primer, the more stable hybrid complex can be formed with the template at a lower annealing temperature.
A " probe " may be a polynucleotide that specifically binds to a particular target sequence. The polynucleotide may be DNA or ribonucleic acid (RNA). The polynucleotide may be in single stranded form. The polynucleotide may also be a polynucleotide which is not only composed of a natural nucleotide but also a natural nucleotide, an analogue of a natural nucleotide, a sugar, a base or a phosphate site of a natural nucleotide, which is capable of being hybridized to a complementary nucleotide by hydrogen bonding And nucleotides selected from the group consisting of combinations thereof. The polynucleotide comprises a peptide nucleic acid (PNA). The polynucleotide can be detected, for example, in such a manner that a detectable label (e.g., Cy3, Cy5 fluorescent substance) is attached to the polynucleotide or the complex to which the polynucleotide or the conjugate is bound, May be attached to the 5 'end.
The composition for confirming exercise performance may be a liquid or a solid composition. The composition for confirming exercise performance may include reagents for dissolving and maintaining marker polynucleotides such as water, buffer, and the like. The buffer may be, for example, a hybridization buffer.
Another aspect provides a kit for identifying exercise performance comprising at least one marker polynucleotide selected from the group consisting of a first marker polynucleotide to a 115th marker polynucleotide.
The kit comprising a first set comprising a first marker polynucleotide to a 54 marker polynucleotide, a second set comprising a 55 marker polynucleotide to a 69 marker polynucleotide, and a second set comprising a 70 marker polynucleotide And a third set comprising at least one marker polynucleotide, at least one marker polynucleotide, and at least one marker polynucleotide.
The "first marker polynucleotide to the 115th marker polynucleotide" and "one or more marker polynucleotides selected from the group consisting of" are as described for the composition for confirming exercise performance. The kit may include, in addition to the marker polynucleotide, a hybridization reagent or a buffer for hybridization with the target nucleic acid.
Another aspect provides a microarray for confirming exercise performance, comprising a substrate on which at least one marker polynucleotide selected from the group consisting of a first marker polynucleotide to a 115th marker polynucleotide is immobilized on a surface.
Wherein the microarray comprises a first set comprising first marker polynucleotide to 54 marker polynucleotides, a second set comprising 55 marker polynucleotides to 69 marker polynucleotides, and a second set comprising 70 marker polynucleotides, And a third set comprising a polynucleotide to a 115th marker polynucleotide, all of the marker polynucleotides in the set of one or more marker polynucleotides are immobilized on the surface.
In the above-mentioned microarray for confirming exercise performance, the "first marker polynucleotide to the 115th marker polynucleotide" and "one or more marker polynucleotide selected from the group consisting thereof" are as described for the composition for confirming exercise performance . The exercise performance may be cardiopulmonary endurance, strength, speed, or a combination thereof.
The term " polynucleotide microarray " refers to a group of polynucleotides immobilized on a substrate at a high density. The polynucleotide groups may be immobilized in a certain region. Such microarrays are well known in the art. Microarrays are described, for example, in U.S. Patent Nos. 5,445,934 and 5,744,305. In addition, a method of using photolithography is generally known as a method of manufacturing the microarray. When photolithography is used, by repeating the step of exposing a certain area on the surface of the substrate coated with the removable group-protected monomer to an energy source to remove the protecting group and coupling the protected monomer with the removable group, the array of polynucleotides Can be produced. In this case, the polynucleotide immobilized on the polynucleotide microarray is synthesized by extending the monomers one by one. Further, according to the spotting method, the microarray is immobilized by immobilizing the synthesized polynucleotide at a predetermined position. Methods for producing such polynucleotide microarrays are described, for example, in U.S. Patent Nos. 5,744,305, 5,143,854, and 5,424,186. The above literature on polynucleotide microarrays and methods for their preparation is incorporated herein by reference in its entirety.
Each marker polynucleotide that is immobilized on the surface of the substrate may comprise a plurality of polynucleotides having identical nucleotides in a single base polymorphic site in separate distinct regions.
The plurality of polynucleotides may have a length from the 5 'terminal nucleotide to a single nucleotide polymorphic site entire nucleotide and a length from the nucleotide next to the single nucleotide polymorphic site to the 3' terminal nucleotide, a single nucleotide polymorphic site full nucleotide from the 5 ' Is longer than the length from the nucleotide following the single nucleotide polymorphic site to the 3 ' terminal nucleotide, and the length from the 5 ' terminal nucleotide to the single nucleotide polymorphic site pre-nucleotide is from the nucleotide next to the single nucleotide polymorphic site to the 3 ' terminal nucleotide Which is shorter than the length of < / RTI > The exercise performance may be cardiopulmonary endurance, strength, speed, or a combination thereof.
Another aspect relates to a method for identifying a nucleic acid comprising contacting a nucleic acid-containing sample separated from an individual with one or more marker polynucleotides selected from the group consisting of first to 115th marker polynucleotides for confirming exercise performance as described above to hybridize the nucleic acid with the marker polynucleotide ; And determining the presence or absence of a single base polymorphism of at least one of the first marker polynucleotide to the 115th marker polynucleotide in the nucleic acid from the resulting hybridization product to provide a SNP profile of the nucleic acid. To obtain the required information.
The method includes, for example, contacting a nucleic acid-containing sample separated from an individual with a marker polynucleotide in a set of one or more marker polynucleotides selected from the group consisting of first to third sets to hybridize the nucleic acid with the marker polynucleotide ; And determining the presence or absence of at least one single base polymorphism of the marker polynucleotide in the first to third sets in the nucleic acid from the obtained hybridization product to provide the SNP profile of the nucleic acid.
The method may further comprise identifying a single nucleotide polymorphism in a marker polynucleotide of 70% or more, such as 70%, 80%, 90%, 95%, 999% or 100% of the marker polynucleotides in the first to third sets, It may be determined that the exercise performance of the individual is superior to that of the non-athlete or other athlete.
The method comprises contacting a nucleic acid-containing sample separated from an individual with one or more marker polynucleotides selected from the group consisting of first to 115th marker polynucleotides for confirming exercise performance as described above, and hybridizing the nucleic acid with the marker polynucleotide .
The sample may be a biological material derived from an individual. The subject may be a vertebrate animal. The vertebrate may be a mammal. The mammal may be a primate, including human and non-human primates, or a rodent, including mice and rats. In addition, the object may be an object to be an athlete or an athlete. The subject may be an athlete of the athlete requiring an excellent cardiopulmonary function, such as a marathon, or a candidate thereof, or an athlete of the exercise requiring an excellent muscle strength such as a weight lifter, or a candidate thereof, It can be an athlete. In addition, the control subject may be a random entity, an athlete, or a non-candidate entity. The subject may be male or female. The subject may be an Asian. The Asian may be Korean, Chinese or Japanese. The subject may be a Korean. The sample may be frozen or left in a natural state. The biological material may be fresh or preserved organ or tissue specimen or solid tissue such as biopsy or aspirate; Blood or blood constituent; Bodily fluids such as cerebrospinal fluid, amniotic fluid, peritoneal fluid, or interstitial fluid; Cells from any time during pregnancy or development of the individual, or combinations thereof. The tissue sample may also be primary or cultured cells or cell lines. The sample may include a compound that is not naturally mixed with biological materials such as preservatives, anticoagulants, buffers, fixatives, nutrients, antibiotics, and the like. The biological sample can be, for example, bone, urine, mucus, saliva, tears, blood, plasma, serum, sputum, spinal fluid, pleural fluid, nipple aspirate, lymphatic fluid, airway fluid, intestinal fluid, Cerebrospinal fluid, intracranial fluid, ascites, cystic tumor fluid, positive fluid, rectal swab, or a combination thereof. The sample may already be isolated from the subject. The method may be in vitro or in vitro.
The contacting may be accomplished by incubating the sample and a marker polynucleotide, e. G., A marker polynucleotide on a microarray, in a liquid medium. The incubation can be carried out without stirring or stirring. The liquid medium may be water, buffer, or a combination thereof. The liquid medium may be a PCR reagent mixture comprising a PCR reagent. The incubation may be performed at an appropriate temperature at which hybridization occurs. The hybridization temperature may be 4 ° C to 65 ° C, for example 45 ° C to 65 ° C, 50 ° C to 65 ° C, 55 ° C to 65 ° C, or 60 ° C to 65 ° C.
The contacting may further comprise labeling the nucleic acid separated from the subject with a detectable label. The detectable label is as described above. As a result, the hybridized result can be confirmed by measuring the signal emitted from the detectable label.
The method may include determining the presence or absence of a single base polymorphism of at least one of the first marker polynucleotide to the 115th marker polynucleotide in the nucleic acid from the resulting hybridization product to provide the SNP profile of the nucleic acid. The SNP profile of the nucleic acid may be information on the presence of minor allele and major allele shown in Tables 1 to 3 and whether or not they exist as homozygotes or variants.
In the method, the hybridizing step comprises contacting the nucleic acid-containing sample separated from the control subject with a marker polynucleotide for confirming the exercise performance, as described above, for example, a marker polynucleotide on a microarray to convert the nucleic acid into the marker polynucleotide And comparing the SNP profile of the nucleic acid of the subject with the SNP profile of the control subject. The control entity may be an entity in which the SNP profile in one or more of the first to 115th marker polynucleotides is known. In addition, the SNP profile of the control subject may be one that is already known by other means, as well as being known by the contacting step. Other methods may be, for example, sequencing, and the like. In addition, the control subject may be an individual who has actually measured the exercise performance of the individual, for example, a cardiopulmonary function such as cardiopulmonary endurance, or an exercise capacity actually measured. The measurement may be by a measurement method known in the art.
In this specification, the utility of a single nucleotide polymorphic marker used to identify an individual's motor performance can be judged by a low p-value and a high association disequilibrium. A high association disequilibrium may mean that these SNPs have a tendency to inherit together when chromosomal recombination occurs. Thus, from a genetic point of view, these SNPs may appear as a single block or cluster specifically for people with cardiovascular endurance or muscle strength.
In this specification, a single base polymorphism (SNP) is used as is commonly known in the art. A single nucleotide polymorphism can represent a single nucleotide polymorphism present in the genome within a population.
The method comprises the steps of incubating a nucleic acid-containing sample in the presence of a primer, such as multiple primers, prior to contacting, and performing PCR, for example, multiplex PCR to obtain an amplified nucleic acid product, wherein the primer comprises a first marker polynucleotide To < RTI ID = 0.0 > 115 < / RTI > marker polynucleotides.
Another aspect is a method for detecting a nucleic acid comprising contacting a nucleic acid-containing sample separated from an individual with one or more marker polynucleotides selected from the group consisting of first to 115th marker polynucleotides to hybridize the nucleic acid with the marker polynucleotide; And determining the presence or absence of at least one single base polymorphism of the first marker polynucleotide to the 115th marker polynucleotide in the nucleic acid from the resulting hybridization product to provide the SNP profile of the nucleic acid, Indicating the presence of a minor allele or major allele of the SNPs shown in Tables 1 to 3; Determining that the subject has a high or high possibility of performing an exercise if the subject has at least one allele associated with the exercise performance among the minor allele and major allele of the SNP shown in Tables 1 to 3; The method comprising the steps of: The exercise performance may be compared to a control group or an individual whose performance of exercise is known.
The method includes, for example, contacting a nucleic acid-containing sample separated from an individual with a marker polynucleotide in a set of one or more marker polynucleotides selected from the group consisting of first to third sets to hybridize the nucleic acid with the marker polynucleotide ; And determining the presence or absence of at least one single base polymorphism in the first to third set of marker polynucleotides in the nucleic acid from the resulting hybridization product to provide the SNP profile of the nucleic acid, 1 < / RTI > to 3 of the SNP; If one or more alleles associated with exercise performance are present in the minor allele and major allele of the SNPs of the SNP profile shown in Tables 1 to 3, the subject may have a higher exercise performance ability than a non-athlete or other athlete And determining that the high possibility is high.
In the method, the hybridizing step comprises contacting the nucleic acid-containing sample separated from the control subject with one or more marker polynucleotides selected from the group consisting of the first to 115th marker polynucleotides to hybridize the nucleic acid with the marker polynucleotide And comparing the SNP profile of the nucleic acid of the subject with the SNP profile of the control subject. The above-mentioned individuals or control individuals are as described above.
The method may further comprise identifying a single nucleotide polymorphism in a marker polynucleotide of 70% or more, such as 70%, 80%, 90%, 95%, 999% or 100% of the marker polynucleotides in the first to third sets, It may be determined that the exercise performance of the individual is superior to that of the non-athlete or other athlete.
Another aspect is a computer-readable medium containing computer executable instructions for identifying an athletic performance performance of an entity, comprising: at least one marker selected from the group consisting of a first marker polynucleotide to a 115th marker polynucleotide; Data indicative of polynucleotides; And a routine stored on the computer-readable medium and adapted to be executed by a processor for verifying motion performance of the entity with respect to the one or more markers.
&Quot; Computer-readable medium " is an information storage medium that can be accessed by a computer using commercially available or custom-made interfaces. The computer-readable medium may be embodied in a computer-readable medium, such as a memory (e.g., RAM, ROM, flash memory, etc.), an optical storage medium (e.g., CD- ), Punch cards, or other commercially available media.
The method of obtaining the information required for the above-mentioned exercise performance confirmation and the one or more marker polynucleotides selected from the group consisting of the first marker polynucleotide to the 115th marker polynucleotide can be carried out in a computer- (computer executable instructions), which may be implemented in whole or in part. For example, the method for obtaining the information required for the exercise performance check may be implemented in hardware. The method for obtaining the information required for the exercise performance check may be implemented in software stored on, for example, one or more memory or other computer readable media and implemented on one or more processors. The processor may be coupled to one or more controllers, a calculation unit, and / or other units of the computer system, or may be portable to the desired firmware. When being transplanted into software, the routines may be stored in a computer readable memory such as RAM, ROM, flash memory, magnetic disk, laser disk, or other storage medium. The software may also be stored on a computer device over a communication channel, such as, for example, via a telephone line, the Internet, a wireless connection, or the like, or via a transportable medium, such as a computer readable disc, Lt; / RTI >
The various steps of the methods described above may be implemented as a variety of blocks, operations, tools, modules, and techniques that may be implemented in hardware, firmware, software, or a combination of hardware, firmware, and / or software. Some or all of the blocks, operations, techniques, etc., when implemented in hardware, may be implemented in a custom IC, an application specific integrated circuit (ASIC), a field programmable logic array (FPGA), a programmable logic array ), And the like.
When implemented in software, the software may be stored in a computer-readable medium, such as a magnetic disk, an optical disk, or other storage medium, a RAM or ROM or flash memory, a processor, a hard disk drive, an optical disk drive, Lt; / RTI > The software may also be communicated to a user or computer system via a delivery method including, for example, a computer readable disc or other portable computer storage mechanism. A computer-readable medium is disclosed, for example, in WO2010-004591A. This patent document is incorporated herein by reference in its entirety.
According to a composition for confirming exercise performance and a kit for confirming exercise performance according to one aspect, it can be effectively used for confirming exercise performance.
According to the microarray for confirming the exercise performance according to one aspect, it can be efficiently used for confirming the exercise performance.
According to the method for obtaining information required for confirming the exercise performance according to another aspect, it is possible to efficiently obtain the information required for the exercise performance check.
According to another aspect of the present invention, there is provided a computer-readable medium having a computer-executable program for verifying an exercise performance of an individual.
Hereinafter, the present invention will be described in more detail with reference to examples. However, these examples are for illustrative purposes only, and the scope of the present invention is not limited to these examples.
Example 1: For checking exercise performance Single nucleotide polymorphism (SNP) Marker selection
(1) Research subjects
The study group consisted of 13 individuals and 18 individuals in international and domestic cardiopulmonary endurance groups, 18 individuals and 19 persons in international and national maximum strength groups, 9 persons in international and domestic speed groups, and a total of 112 persons in total 26 persons Respectively.
International and domestic standards are as follows.
- International level: Olympic and World Championships medalist or international / domestic record holder
- Domestic level: a player who has a career similar to an international player but does not have a national player
Also, for the cardiopulmonary endurance group, it was a marathon male athlete with a record of 2 hours and 12 minutes at the convention.
After the participants explained the purpose and method of the experiment in detail, the experiment was conducted with the written informed consent and IRB approval.
(2) Analysis method
1) DNA extraction field - genetic association Genotype analysis (Genome-Wide Association Genotyping)
Peripheral blood samples were used for DNA extraction. After isolating genomic DNA from the sample, the concentration of DNA was determined at a A260 / A280 ratio using a spectrophotometer as a transparent eluent obtained in order to confirm whether DNA was extracted.
Samples were analyzed using Affymetrix Genome-Wide Human SNP array 6.0 from DENEI Link (Songpa-gu, Seoul, Korea). Affymetrix Genome-Wide Human SNP array 6.0 contained SNPs of 904,333 genomes and 946,000 genomic unit copy number variations. Approximately 500 ng of genomic DNA was digested with two restriction enzymes, NSP I and Sty I, according to the Affymetrix protocol. These digested fragments were then combined with specific adapters containing a universal PCR priming sequence. PCR amplification using universal primers performed an optimized reaction to amplify fragments between 200-1,100 base pairs. The fragmentation step was then finalized using iotinylated nucleotides after reducing the PCR products to fragments of approximately 25-50 bp. The products thus classified or marked were mixed with chips and washed and detected. Images were analyzed using GeneChip operating system software (Affymetrix, Santa Clara, CA, USA). For the data from the chip, the internal QC was measured: the QC call rate (dynamic model algorithm) always exceeded 86%, and the heterozygosity of the X chromosome correctly discriminated the sex of the individual. Genotyping was performed using the Birdseed v2 algorithm.
2) DNA amplification and display
All DNA was prepared for genotyping according to the Affymetrix Genome-Wide Human SNP Nsp / Sty 6.0 instructions. Briefly, the titration of each DNA was split into two overlapping 96-well plates. After that, 48 samples of each plate were treated with Sty I or NSP restriction enzyme. After inactivation of the restriction enzyme, the sticky end of the digested DNA was ligated with Nsp or Sty I adapter / primer using T4 ligase. The appropriate amount of each combined product was divided into four separate plates for PCR amplification using universal primers. The products of the four PCR reactions to individual subjects were purified to plate form after binding. The product of each amplified DNA sample was determined by UV spectrophotometry using a microplate reader. All DNA with a lower than expected (4-5 mg / ml) or abnormal size distribution was marked and not further processed. Each DNA fragment was then sub-digested to a size of less than 200 bp using DNase I, and the size distribution of the subdivided DNA fragments was assessed using electrophoresis in agarose gel, a 4% agarose gel in Tris-Acetate-EDTA buffer Respectively. DNA samples that appeared to be abnormal fragments did not progress anymore. Samples that passed this quality check step were finally classified or labeled with biotinylated nucleoides using Terminal Deoxynucleotidyl Transferase. The hybridization solution was added to the final labeled product, denatured and then added to Genome-Wide Human SNP Array 6.0 (1 array / 1sample). Each array was placed in a GeneChip® Hybridization Oven 640 and incubated at 50 ° C with rotation at 60 rpm for 16 hours. After hybridization was complete, DNA samples were removed from each microarray and replaced with Array Holding Buffer. Microarrays were washed with Fluidics Station 450 (Affymetrix, Santa Clara, Calif.) Using the GenomeWideSNP6_450 protocol.
3) Scan and Genotype analysis ( genotyping )
We used the GeneChip® Scanner 3000 7G with an automatic stacker to inspect each array to obtain an image of the array and the GeneChip® Operating System (GCOS) software for the generation of the raw .DAT files Respectively. For feature extraction (CEL file), each .DAT image was GCOS. All .CEL files were subjected to a low-level Quality Control (QC) analysis in Genotyping Console 2.1 (Affymetrix) to determine suitability for genotype analysis use. The QC analysis included an image quality test to confirm that there were no obvious manufacturing or physical defects. Thereafter, the QC Call rate (generated automatically when the .CEL file was imported into the genotype console) test for approximately 3,100 SNPs known to be sensitive to DNA quality was tested. This step included separately performing a QC call rate evaluation on SNPs treated with NSP and Sty I.
4) Quality Control ( QC )
Genome-Wide Human SNP Array 6.0 was used to acquire SNP information and to perform QC for samples and SNPs.
The QC for the samples proceeded in two steps. First, samples with a call rate of less than 97%, which indicates the success rate of each sample, were excluded from the analysis. Second, gender information for the sample is presented through the experiment.
The QC for SNP was performed in four steps. First, SNPs that do not satisfy the Hardy-Weinberg Equilibrium (HWE) were excluded from the analysis. The permutation test was performed to test whether the HWE was satisfied and excluded from the analysis when p <0.0000001. Second, SNPs with less than 95% call rate per analysis group were excluded from the analysis. Third, when the MAF (Minor Allele Frequency) was less than 1% in each analysis group, it was excluded from the analysis. Finally, we performed a cluster QC plot to check for genotype errors and performed QC to exclude genotype errors in the analysis of SNPs with very significant p-values of less than 0.0001 after statistical analysis .
(3) Data processing method
Association studies were conducted in male subjects when all SNPs were located on autosomes, in the pseudo-autosomal region of chromosome X, or in mitochondria, and when SNPs were located on the Y chromosome.
In this example, the number of female samples was not sufficient and the X chromosome was excluded from the analysis. The SNPs were composed of two alleles, major and minor. If alleles were A and B, the genotype of each sample was AA (Major homozygote), AB (Heterozygote) and BB (Minor homozygote). A variety of genetic models were applied to this study. In this example, Dominant (AA vs. AB + BB), Recessive (AA + AB vs. BB), Additive (AA vs. AB vs. BB) and Allele (A vs. B) The Chi-square test was used for the Dominant, Recessive and Allele models and the Cochran-Armitage Trend test was used for the additive models. The Jonckheere-Terpstra test was performed on all models with the nonparametric method when the sample size was not large enough and it was difficult to apply the parametric method.
All statistical hypothesis tests were performed with a two-tailed test. The statistical significance level was set at 5%, ie, α = 0.05. For statistical data analysis, plink (http://pngu.mgh.harvard.edu/~ purcell / plink /) version 1.0.7 and SAS (SAS Institute Inc. Cary, NC) version 9.1.3 were used.
Example 2. Derivation of the number of SNPs related to exercise performance and the derived SNP analysis
(One) On GWAS Of SNPs related to exercise performance
1) Determine the SNP of the final analysis target through the total number of SNPs to be analyzed and QC
A total of 867,268 SNPs were present in the autosomes, accounting for 95.9% of the total. The total number of SNPs present in the pseudo-autosomal region of chromosome X was 363, which was 0.04% of the total, and the SNPs present in the mitochondrial were total 103, which was 0.01% of the total. In addition, the number of analyzed SNPs on X chromosome was 36,351, which was 4.02% of the total, and the total number of SNPs in the Y chromosome was 248, which was 0.03% of the total. In the case of X chromosome, the number of female participants was too small to be excluded from comparison and analysis by SNP group.
As a result of the QC of the samples, a total of 867,982 SNPs were used for the international level CPR group vs. CPR group. General population, domestic level cardiopulmonary endurance group, etc. General population and international + domestic level cardiovascular endurance group vs. 630,309, 616,516, and 646,020 SNPs in the general population, respectively. General population, domestic maximum strength group, etc. General population group and international + domestic level maximum power group. 619,874, 619,370, 647,166 SNPs, international level speed group, General population, domestic level speed group, etc. General people group and international + domestic level speed group etc. 614,822, 615,432, and 597,819 SNPs were included in the analysis, respectively.
2) GWAS results
The genome-wide association was analyzed using Affymetrix Genome-Wide Human SNP array 6.0 in the DNALink (Songpa-gu, Seoul, Korea) SNP, and speed-related SNP. Genome-wide association plot (Manhattan Plot) was used to derive target SNPs related to exercise performance. The number of target SNPs related to exercise performance was then determined according to the p-value.
Table 5 shows the number of target SNPs according to the p-value. When the significance level threshold is p <.001, SNP is the international level cardiopulmonary endurance player. General public, domestic level cardiopulmonary endurance player etc. Public and international level + domestic level players vs. In general, 806, 780 and 924 SNPs were derived, respectively. The general public, the maximum strength players in domestic level. General and international level + domestic level players vs. In general, 709, 903 and 882 SNPs were derived, respectively. General players, domestic speed players, etc. General and international level + domestic level players vs. And 925, 1,060, and 741, respectively. As a result, there were 78 SNPs (cardiovascular vs. general) related to cardiopulmonary endurance, 26 SNPs (weightlifter vs. general) and a speed-related SNP 81 were derived.
Case 1 = MT vs. Control, Case 2 = SMT vs.. Control, Case 3 = MT + SMT vs Control, Case 4 = WL vs Control, Case 5 = SWL vs Control, Case 6 = = SP + SSP vs Control. Con = Control group, MT = International level marathoner, SMT = Domestic level marathoner, WL = International level weightlifter, SWL = Domestic level weightlifter, SP = International level shorttrack and speed skater, SSP = Domestic level Short-cut and speed skating athletes
(2) Dielectric characteristics of cardiopulmonary endurance-related SNPs
1) Type and location of international level cardiopulmonary endurance related SNP
Of the internationally selected cardiopulmonary endurance-related SNPs selected by GWAS, the total of 78 SNPs satisfying p-value < 0.0001 were selected, and a section having two or more SNPs within 100 Kb was selected as a section, Table 6 shows the types and the positions of the test pieces. There were a total of 78 SNPs related to cardiopulmonary endurance at the international level, but 24 SNPs that existed alone were omitted, and 54 SNPs in a region having two or more SNPs within a distance of 100 Kb were selected. As shown in Table 8, the cardiopulmonary endurance-related SNPs were present in 17 sections, and the autosomes 1, 2, 3, 5, 7, 9, 10, 11, 17 And 21, respectively.
CHODL-AS1
2) Type and location of each level of cardiopulmonary endurance-related SNP in Korea
A total of 77 SNPs satisfying the p-value <.0001 among the selected domestic cardiopulmonary endurance-related SNPs through GWAS were selected, and a section having two or more SNPs within 100 Kb was selected as a section, and SNPs Are shown in Table 7. < tb > < TABLE > A total of 77 SNPs related to cardiopulmonary endurance at the domestic level were excluded, but 31 single SNPs were omitted, and 46 SNPs in a region having two or more SNPs within a distance of 100 Kb were selected. As shown in Table 7, the domestic level cardiopulmonary endurance-related SNPs were present in a total of 16 sections, and autosomes 2, 3, 5, 6, 9, 10, 11, 13 , No. 20 and No. 20, respectively.
WDR36
RPS16P5
3) SNPs appearing only at various intersections of cardiopulmonary endurance players and at international level players
Among the international level cardiopulmonary endurance-related SNPs selected through GWAS, there were 78 SNPs satisfying the p-value <.0001. However, 24 SNPs that exist alone were omitted and two or more SNPs within a distance of 100 Kb The number of SNPs was 54 in Korea, and the number of SNPs in Korea was 46 and the number of cardiovascular endurance - related SNP was 67 in Korea.
As shown in Table 8, among the 54 SNPs related to cardiopulmonary endurance at the international level, there were only 40 SNPs that only international players had, and there were no SNPs common to the international and national players. On the other hand, there are 14 SNPs that are common in international + domestic level groups as well as international level players.
Level 1 = SNPs present only at international level players, Level 2 = SNPs common at international and national level players, and SNPs at level 3 = International and International + domestic level.
(3) Dielectric characteristics of maximal strength-related SNP
1) Type and position of each international level maximum strength-related SNP
A total of 26 SNPs satisfying the p-value <.00001 among the selected international-level strength-related SNPs through GWAS were selected, and a section having two or more SNPs within 100 Kb was selected as a section, The types and locations are shown in Table 9. There were a total of 26 SNPs related to the international level of strength, but omitting the information of 11 SNPs alone, 15 SNPs were selected in a region having two or more SNPs within a distance of 100 Kb. As shown in Table 9, the muscle-related SNPs were present in all six sections and were present in autosomes 2, 3, 8, 10 and 20.
2) Types and positions of the maximum strength-related SNPs at each level in Korea
A total of 72 SNPs satisfying the p-value <.0001 among the selected maximum local strength-related SNPs through GWAS were selected, and a section having two or more SNPs within 100 Kb was selected as a section, and SNPs Are shown in Table 10. < tb > < TABLE > There were a total of 72 SNPs at the domestic level, but 23 SNPs alone were omitted, and 49 SNPs were selected in a region having two or more SNPs within a distance of 100 Kb. As shown in Table 10, the highest SNPs in Korea were present in all 10 regions and existed in Autosomes 3, 5, 6, 8, 9, 10 and 13 .
3) SNPs appearing only at various intersections and at international level players of maximum strength players
A total of 26 SNPs meeting the p-value <.0001 among the internationally selected maximum strength-related SNPs selected through GWAS were excluded, but only 11 SNPs were omitted and more than 2 SNPs within 100 Kb There were 15 SNPs in the zone, and the SNPs of the domestic level players satisfying the above criteria were 49, and the maximum strength - related SNPs at the international + domestic level were 62.
As shown in Table 11, among the 15 SNPs related to the highest level of strength at the international level, only SNPs having only international level players had 12 SNPs. As with the results of the marathon group, There was no SNP. On the other hand, there are three SNPs that are common among the international + domestic level group as well as the international level players.
SNPs that exist only at the first level = international level, second level = SNPs that overlap at the international and domestic levels, third level = SNPs that appear in the international + domestic level as well as the international level.
(4) speed Dielectric characteristics of related SNPs
1) Type and location of international level speed related SNP
Among 81 SNPs that satisfy the p-value <.0001, SNPs selected from international speed-related SNPs selected through GWAS were 81 SNPs within 100 Kb, and SNPs with more than 2 SNPs were selected as SNPs. Type and position are shown in Table 12. A total of 81 SNPs related to the international level speed were omitted. However, only 35 SNPs existing at a distance within 100 Kb were omitted and 46 SNPs having 2 or more SNPs were selected. As shown in Table 12, the speed-related SNPs were present in a total of 20 sections, and the autosomes 1, 3, 4, 6, 7, 8, 10, 11, 12 13, 18 and 20, respectively.
CASZ1
LOC349160
TRPT1
2) Type and position of SNP related to each level in Korea
Among the SNPs selected by GWAS, 120 SNPs satisfying the p-value <.0001 were selected. Among them, SNPs having two or more SNPs within 100 kb were selected as one section, The types and positions are shown in Table 13. A total of 120 SNPs were found in Korea, but 38 single SNPs were omitted, and 82 SNPs in a region with two or more SNPs within a distance of 100 Kb were selected. As shown in Table 13, the SNPs related to the domestic level of speed were present in a total of 29 segments, and the autosomes 1, 2, 3, 4, 5, 6, 7 and 9 , 10, 11, 12, 13, 20 and 21, respectively.
C9
TRPT1
3) SNPs appearing only at the intersection of various speed group players and at international level players
A total of 81 SNPs satisfying the p-value <.0001 among the international-level speed-related SNPs selected through GWAS were omitted, but 35 SNPs existing alone were omitted, and two SNPs within a distance of 100 Kb There were 46 SNPs in the interval, and the SNPs of the domestic level players meeting the above criteria were 82 and the SNPs related to the speed of the international + domestic level were 30.
As shown in Table 15, among the 46 speed-related SNPs at the international level only 39 international SNPs were held. Only SNPs at the international level and at the domestic level are shared by four SNPs and international level players In addition, there are three SNPs that are common among the international + domestic level groups.
SNPs that exist only at the first level = international level, second level = SNPs that overlap at the international and domestic levels, third level = SNPs that appear in the international + domestic level as well as the international level.
As a result, a total of 54 SNPs related to cardiopulmonary endurance (40 at the international level, 14 common at the international level and at the international + domestic level, see Table 8) A total of 46 SNPs (39 international, 39 international and international level players, 4 international and international level players and 3 international and domestic level players, see Table 11) (3) (see Table 14), indicating that these SNPs can be used to confirm exercise performance.
SEQUENCE LISTING <110> Seoul Olympic Sports Promotion Foundation <120> Composition, kit or microarray for indentifying athletic performance comprising marker polynucleotide, and method for obtaining information for indentifying athletic performance using the same <130> PN105319 <160> 115 <170> PatentIn version 3.5 <210> 1 <211> 51 <212> DNA <213> Homo sapiens <220> <221> misc_feature ≪ 222 > (26) <223> n is a, c, g, or t <400> 1 gagattatta gtgcagattt ggtatntatc aggtcagatc ggggctgctg t 51 <210> 2 <211> 51 <212> DNA <213> Homo sapiens <220> <221> misc_feature ≪ 222 > (26) <223> n is a, c, g, or t <400> 2 ctcgttatca aaatcataaa tatgcnttgc acatgtattg cgtgccctgt t 51 <210> 3 <211> 51 <212> DNA <213> Homo sapiens <220> <221> misc_feature ≪ 222 > (26) <223> n is a, c, g, or t <400> 3 ctcacttcct cctctgagcc ccgatngctg tttgttcgta gaccccctag c 51 <210> 4 <211> 51 <212> DNA <213> Homo sapiens <220> <221> misc_feature ≪ 222 > (26) <223> n is a, c, g, or t <400> 4 ttagtacaac agaaagtctg ctttantctt tcctctgctg ttctcaaact g 51 <210> 5 <211> 51 <212> DNA <213> Homo sapiens <220> <221> misc_feature ≪ 222 > (26) <223> n is a, c, g, or t <400> 5 tttcggcaat ataaagtgaa aaccangtac tgtcgggaga ggggctggca t 51 <210> 6 <211> 51 <212> DNA <213> Homo sapiens <220> <221> misc_feature ≪ 222 > (26) <223> n is a, c, g, or t <400> 6 tactgactga gatacctggt tcatcntatt ggcattggtt agacagtggg t 51 <210> 7 <211> 51 <212> DNA <213> Homo sapiens <220> <221> misc_feature ≪ 222 > (26) <223> n is a, c, g, or t <400> 7 aaaaaatgtt aagggcagcc agaganaaag cccagattac ccagaaaggg a 51 <210> 8 <211> 51 <212> DNA <213> Homo sapiens <220> <221> misc_feature ≪ 222 > (26) <223> n is a, c, g, or t <400> 8 tatagacagc agactttgaa aactgngcaa aagtagagaa cctgtcacta c 51 <210> 9 <211> 51 <212> DNA <213> Homo sapiens <220> <221> misc_feature ≪ 222 > (26) <223> n is a, c, g, or t <400> 9 ttgtgcaatt tttgaattgc atattnttct tcaagagcaa aacaaaacat t 51 <210> 10 <211> 51 <212> DNA <213> Homo sapiens <220> <221> misc_feature ≪ 222 > (26) <223> n is a, c, g, or t <400> 10 atgaacttca cacttcaatt tcactncttg gcttggcttc ataaatgttc a 51 <210> 11 <211> 51 <212> DNA <213> Homo sapiens <220> <221> misc_feature ≪ 222 > (26) <223> n is a, c, g, or t <400> 11 catttctacc aatcctgtaa gagagncatg attattgtct gagatgttaa g 51 <210> 12 <211> 51 <212> DNA <213> Homo sapiens <220> <221> misc_feature ≪ 222 > (26) <223> n is a, c, g, or t <400> 12 gctggaatta gaagcaatga actagntgtg aatagaaaaa catggctaag t 51 <210> 13 <211> 51 <212> DNA <213> Homo sapiens <220> <221> misc_feature ≪ 222 > (26) <223> n is a, c, g, or t <400> 13 tttcactcaa tggcagcctt atccantgag ttaagccttt ttcttcttta t 51 <210> 14 <211> 51 <212> DNA <213> Homo sapiens <220> <221> misc_feature ≪ 222 > (26) <223> n is a, c, g, or t <400> 14 cttaaactga aaaagactat tttgangcta tctctggaat tagcacttct a 51 <210> 15 <211> 51 <212> DNA <213> Homo sapiens <220> <221> misc_feature ≪ 222 > (26) <223> n is a, c, g, or t <400> 15 aaatatgacc catattagtt gattgncctt aattcagaaa actggcaact g 51 <210> 16 <211> 51 <212> DNA <213> Homo sapiens <220> <221> misc_feature ≪ 222 > (26) <223> n is a, c, g, or t <400> 16 ttttaagttt aggttcttct tttacnttga caacccccaa tttcatgctg c 51 <210> 17 <211> 51 <212> DNA <213> Homo sapiens <220> <221> misc_feature ≪ 222 > (26) <223> n is a, c, g, or t <400> 17 caagggtgca tttgtatgtg ccctcnaaaa ccctatattt tggggctctt a 51 <210> 18 <211> 51 <212> DNA <213> Homo sapiens <220> <221> misc_feature ≪ 222 > (26) <223> n is a, c, g, or t <400> 18 tttggcgtga ttataaaagc atacancttc aaaggaagta aagaaagaca t 51 <210> 19 <211> 51 <212> DNA <213> Homo sapiens <220> <221> misc_feature ≪ 222 > (26) <223> n is a, c, g, or t <400> 19 tctctgtctt cctcactcct tccatnttaa gtgctcttta gatcaaattt c 51 <210> 20 <211> 51 <212> DNA <213> Homo sapiens <220> <221> misc_feature ≪ 222 > (26) <223> n is a, c, g, or t <400> 20 gagactgggt tggcactgtg atatgncttc cagattagct ttctaacccc a 51 <210> 21 <211> 51 <212> DNA <213> Homo sapiens <220> <221> misc_feature ≪ 222 > (26) <223> n is a, c, g, or t <400> 21 agtgatggca ataccttgat ttagangttt ccttctggtc cactacttca g 51 <210> 22 <211> 51 <212> DNA <213> Homo sapiens <220> <221> misc_feature ≪ 222 > (26) <223> n is a, c, g, or t <400> 22 cctatcttta cattgggtca tttgcnttta atcgtttagt tgtaaaagtt a 51 <210> 23 <211> 51 <212> DNA <213> Homo sapiens <220> <221> misc_feature ≪ 222 > (26) <223> n is a, c, g, or t <400> 23 gcccatgatt tcattactag tgagcntatt ggaatattca attcaaatga g 51 <210> 24 <211> 51 <212> DNA <213> Homo sapiens <220> <221> misc_feature ≪ 222 > (26) <223> n is a, c, g, or t <400> 24 tgctgtatat cagtctttcg atttcntttt gagaatggga gccttagtgc a 51 <210> 25 <211> 51 <212> DNA <213> Homo sapiens <220> <221> misc_feature ≪ 222 > (26) <223> n is a, c, g, or t <400> 25 gagaggaacc tggcagagag attaangcag gagcagattc agcaggatag g 51 <210> 26 <211> 51 <212> DNA <213> Homo sapiens <220> <221> misc_feature ≪ 222 > (26) <223> n is a, c, g, or t <400> 26 tgacattgcc tgagctatta cttacnttag ttctgccata atcatcttat t 51 <210> 27 <211> 51 <212> DNA <213> Homo sapiens <220> <221> misc_feature ≪ 222 > (26) <223> n is a, c, g, or t <400> 27 tgttcctgga gctctcacgt gggccntttt gtgttgtgaa tgcgtctgga g 51 <210> 28 <211> 51 <212> DNA <213> Homo sapiens <220> <221> misc_feature ≪ 222 > (26) <223> n is a, c, g, or t <400> 28 gcacacactg cattcatcgt acaccntgaa gctggccctc tccctgtccc a 51 <210> 29 <211> 51 <212> DNA <213> Homo sapiens <220> <221> misc_feature ≪ 222 > (26) <223> n is a, c, g, or t <400> 29 tccagagagc aatgtagccc aaactnaaga atgagaatga actgggacag g 51 <210> 30 <211> 51 <212> DNA <213> Homo sapiens <220> <221> misc_feature ≪ 222 > (26) <223> n is a, c, g, or t <400> 30 caaaacattg cccaaagcat gtgttngatg attcatttaa tcttctagca t 51 <210> 31 <211> 51 <212> DNA <213> Homo sapiens <220> <221> misc_feature ≪ 222 > (26) <223> n is a, c, g, or t <400> 31 caaaatcatg catgagtaaa aagtancatt caaagtgcaa gacagactaa t 51 <210> 32 <211> 51 <212> DNA <213> Homo sapiens <220> <221> misc_feature ≪ 222 > (26) <223> n is a, c, g, or t <400> 32 gcaatggcat aatatgctga aagaanatga taactgtcaa ccagatttat a 51 <210> 33 <211> 51 <212> DNA <213> Homo sapiens <220> <221> misc_feature ≪ 222 > (26) <223> n is a, c, g, or t <400> 33 cacactgggc ctctactcta cttttngatg tttaggtatg tttagataca c 51 <210> 34 <211> 51 <212> DNA <213> Homo sapiens <220> <221> misc_feature ≪ 222 > (26) <223> n is a, c, g, or t <400> 34 caggccaggt ggatacacct aaaatngcac tcttaactgc tagagccaag a 51 <210> 35 <211> 51 <212> DNA <213> Homo sapiens <220> <221> misc_feature ≪ 222 > (26) <223> n is a, c, g, or t <400> 35 actatcttgt gctccattgt gaatangggt gtggactgga ccttcagcat c 51 <210> 36 <211> 51 <212> DNA <213> Homo sapiens <220> <221> misc_feature ≪ 222 > (26) <223> n is a, c, g, or t <400> 36 ggtctgatag gaggttgagg tggtgnctcc aatgtaccat tgtttcatat t 51 <210> 37 <211> 51 <212> DNA <213> Homo sapiens <220> <221> misc_feature ≪ 222 > (26) <223> n is a, c, g, or t <400> 37 agcagcctcc tcttggtggt aatcanggcc catttgcacc tcctacatct c 51 <210> 38 <211> 51 <212> DNA <213> Homo sapiens <220> <221> misc_feature ≪ 222 > (26) <223> n is a, c, g, or t <400> 38 actttgtctc ctctctagct ctttcngggc tgtaggggta tgggcctttc c 51 <210> 39 <211> 51 <212> DNA <213> Homo sapiens <220> <221> misc_feature ≪ 222 > (26) <223> n is a, c, g, or t <400> 39 cgacctcctt tgactcagca tttccnaggc tctctgacca cagaatcctt t 51 <210> 40 <211> 51 <212> DNA <213> Homo sapiens <220> <221> misc_feature ≪ 222 > (26) <223> n is a, c, g, or t <400> 40 gaggctgtgc gtgggccgga tagganctgt ttaatatctg agaggaaaat a 51 <210> 41 <211> 51 <212> DNA <213> Homo sapiens <220> <221> misc_feature ≪ 222 > (26) <223> n is a, c, g, or t <400> 41 gggacaggct aaagatggaa catggnatac ctaacaggac ttcagaagaa a 51 <210> 42 <211> 51 <212> DNA <213> Homo sapiens <220> <221> misc_feature ≪ 222 > (26) <223> n is a, c, g, or t <400> 42 attcatatgt aacacataga tgtatnacaa tagctcagga ttcattcgaa a 51 <210> 43 <211> 51 <212> DNA <213> Homo sapiens <220> <221> misc_feature ≪ 222 > (26) <223> n is a, c, g, or t <400> 43 ggctacctag tcttgaaatg ataagnaagg tccattttat ttctaacctt c 51 <210> 44 <211> 51 <212> DNA <213> Homo sapiens <220> <221> misc_feature ≪ 222 > (26) <223> n is a, c, g, or t <400> 44 atttggttaa ggaaattacc agatgncagc acttttatgt tgaaaaatgc a 51 <210> 45 <211> 51 <212> DNA <213> Homo sapiens <220> <221> misc_feature ≪ 222 > (26) <223> n is a, c, g, or t <400> 45 tccagtgcat tatatacgac ttttanattc ttcacacttt tctagtgctg t 51 <210> 46 <211> 51 <212> DNA <213> Homo sapiens <220> <221> misc_feature ≪ 222 > (26) <223> n is a, c, g, or t <400> 46 gatggtttta attgttaaat cggaanttta atttgccatg cttggataac a 51 <210> 47 <211> 51 <212> DNA <213> Homo sapiens <220> <221> misc_feature ≪ 222 > (26) <223> n is a, c, g, or t <400> 47 gtttttatgg aaactaccat ttactntgtg tctactatgt gccagggggc c 51 <210> 48 <211> 51 <212> DNA <213> Homo sapiens <220> <221> misc_feature ≪ 222 > (26) <223> n is a, c, g, or t <400> 48 gattgagact tcaaagataa gtggantaaa caagaaaggc tatgggataa g 51 <210> 49 <211> 51 <212> DNA <213> Homo sapiens <220> <221> misc_feature ≪ 222 > (26) <223> n is a, c, g, or t <400> 49 gtagcatggg gaaaatcatt gcttcngaga ggatacagac tgtgaccaag a 51 <210> 50 <211> 51 <212> DNA <213> Homo sapiens <220> <221> misc_feature ≪ 222 > (26) <223> n is a, c, g, or t <400> 50 aagttgtcgt aaatgaattg gaaagnagaa tgtgctaagc ccctatttgc c 51 <210> 51 <211> 51 <212> DNA <213> Homo sapiens <220> <221> misc_feature ≪ 222 > (26) <223> n is a, c, g, or t <400> 51 atagaggaaa aaagagacta ccagtntaac tgattgctag actccaaaat t 51 <210> 52 <211> 51 <212> DNA <213> Homo sapiens <220> <221> misc_feature ≪ 222 > (26) <223> n is a, c, g, or t <400> 52 ccttggatat gtctcccttc acttcnttca ctcgcgtctg tgtgaagaga c 51 <210> 53 <211> 51 <212> DNA <213> Homo sapiens <220> <221> misc_feature ≪ 222 > (26) <223> n is a, c, g, or t <400> 53 atttcacttg attacagctc aaatcntgga caatcaaggt agagtccctt g 51 <210> 54 <211> 51 <212> DNA <213> Homo sapiens <220> <221> misc_feature ≪ 222 > (26) <223> n is a, c, g, or t <400> 54 gattggactt tgtttactgc ccatcnattt actgcacaac gtggatttat g 51 <210> 55 <211> 51 <212> DNA <213> Homo sapiens <220> <221> misc_feature ≪ 222 > (26) <223> n is a, c, g, or t <400> 55 tttatggaag ggtggctgga tgtganacct gggctgaaat atggaataac a 51 <210> 56 <211> 51 <212> DNA <213> Homo sapiens <220> <221> misc_feature ≪ 222 > (26) <223> n is a, c, g, or t <400> 56 ttttgctttg ttaaagttgt cagagngttg ttcagtgagg aataggaggc a 51 <210> 57 <211> 51 <212> DNA <213> Homo sapiens <220> <221> misc_feature ≪ 222 > (26) <223> n is a, c, g, or t <400> 57 ggacagccag gatgctttca ccaccngtaa tatattacaa agtggccaca a 51 <210> 58 <211> 51 <212> DNA <213> Homo sapiens <220> <221> misc_feature ≪ 222 > (26) <223> n is a, c, g, or t <400> 58 ggaaatgggc aaactggaaa ggaacnctga aggtagtccg gcgaggctga g 51 <210> 59 <211> 51 <212> DNA <213> Homo sapiens <220> <221> misc_feature ≪ 222 > (26) <223> n is a, c, g, or t <400> 59 ctttgctttc ttgttaccaa tttgtntaca gaagcaagcc atgttaaaaa t 51 <210> 60 <211> 51 <212> DNA <213> Homo sapiens <220> <221> misc_feature ≪ 222 > (26) <223> n is a, c, g, or t <400> 60 gcaggggcct gggctaagag accgcntagc cctggaatat ttgagatatg c 51 <210> 61 <211> 51 <212> DNA <213> Homo sapiens <220> <221> misc_feature ≪ 222 > (26) <223> n is a, c, g, or t <400> 61 tcaagattag aaaagccctg tcttanagta tccctcaaaa tttatatatt t 51 <210> 62 <211> 51 <212> DNA <213> Homo sapiens <220> <221> misc_feature ≪ 222 > (26) <223> n is a, c, g, or t <400> 62 cctaatgttg cgctttacag ctcacntaga acatttactt atattatcta a 51 <210> 63 <211> 51 <212> DNA <213> Homo sapiens <220> <221> misc_feature ≪ 222 > (26) <223> n is a, c, g, or t <400> 63 aaatttcagc ctaaatccta gaatcngttc tggtttccct gcttgggtca t 51 <210> 64 <211> 51 <212> DNA <213> Homo sapiens <220> <221> misc_feature ≪ 222 > (26) <223> n is a, c, g, or t <400> 64 aagtgagaat aatatttaga ttgganatat gtatgtaagc acgtagcaaa g 51 <210> 65 <211> 51 <212> DNA <213> Homo sapiens <220> <221> misc_feature ≪ 222 > (26) <223> n is a, c, g, or t <400> 65 ctggacattt catgttatca gcatcnttca atatatggtt tttcatgact g 51 <210> 66 <211> 51 <212> DNA <213> Homo sapiens <220> <221> misc_feature ≪ 222 > (26) <223> n is a, c, g, or t <400> 66 atctaggagt gggtttctgg atcacntggt aactctacgt ttaacctttt g 51 <210> 67 <211> 51 <212> DNA <213> Homo sapiens <220> <221> misc_feature ≪ 222 > (26) <223> n is a, c, g, or t <400> 67 attcgaactg agtttcgatt ccagcnctaa cttcaatgtc catgttccta a 51 <210> 68 <211> 51 <212> DNA <213> Homo sapiens <220> <221> misc_feature ≪ 222 > (26) <223> n is a, c, g, or t <400> 68 ttacatatat atttttaaga ccattnggta gcttagcaga cactgttagt g 51 <210> 69 <211> 51 <212> DNA <213> Homo sapiens <220> <221> misc_feature ≪ 222 > (26) <223> n is a, c, g, or t <400> 69 tgcaggagtt tgtccttgca aaaaantaca aaattagctt ggcatggtgg c 51 <210> 70 <211> 51 <212> DNA <213> Homo sapiens <220> <221> misc_feature ≪ 222 > (26) <223> n is a, c, g, or t <400> 70 ggagctcagg aaggaggagc caaacnagga agttctcctc tgctccaagg g 51 <210> 71 <211> 51 <212> DNA <213> Homo sapiens <220> <221> misc_feature ≪ 222 > (26) <223> n is a, c, g, or t <400> 71 gtggtgttta aagccatgac cctgtngctt gaaagaaggt ccttccagta t 51 <210> 72 <211> 51 <212> DNA <213> Homo sapiens <220> <221> misc_feature ≪ 222 > (26) <223> n is a, c, g, or t <400> 72 taaatggact gatctataga taagangtat gaagtaagag gctagacttg a 51 <210> 73 <211> 51 <212> DNA <213> Homo sapiens <220> <221> misc_feature ≪ 222 > (26) <223> n is a, c, g, or t <400> 73 tccttcacca aagaacctat gaccangtgt ttaggtaacc ataactgggg a 51 <210> 74 <211> 51 <212> DNA <213> Homo sapiens <220> <221> misc_feature ≪ 222 > (26) <223> n is a, c, g, or t <400> 74 atcttcaagg tcaaagtctt gggccnaagt aatatcatct ataatgtgaa a 51 <210> 75 <211> 51 <212> DNA <213> Homo sapiens <220> <221> misc_feature ≪ 222 > (26) <223> n is a, c, g, or t <400> 75 aagcaagagt gagcatatgg catggnaact tgagaaagta aaaatgggag a 51 <210> 76 <211> 51 <212> DNA <213> Homo sapiens <220> <221> misc_feature ≪ 222 > (26) <223> n is a, c, g, or t <400> 76 tgattgaaca cagaacaaga gatgancatg gtgtcagact aagtcttaga g 51 <210> 77 <211> 51 <212> DNA <213> Homo sapiens <220> <221> misc_feature ≪ 222 > (26) <223> n is a, c, g, or t <400> 77 ttattcttac catgttttct aatgtntttt gtgccatttc ctgctgttct a 51 <210> 78 <211> 51 <212> DNA <213> Homo sapiens <220> <221> misc_feature ≪ 222 > (26) <223> n is a, c, g, or t <400> 78 atcattaagg tccgggccac ccttantaag tgcctgttaa cagcagcagt c 51 <210> 79 <211> 51 <212> DNA <213> Homo sapiens <220> <221> misc_feature ≪ 222 > (26) <223> n is a, c, g, or t <400> 79 ctccgaaaga ggggaaacta atgatntgag ccccgcgatt gccccagctt a 51 <210> 80 <211> 51 <212> DNA <213> Homo sapiens <220> <221> misc_feature ≪ 222 > (26) <223> n is a, c, g, or t <400> 80 ggagaacaga tcttctttat cttcangtaa gctccaatga ctttcgcaga g 51 <210> 81 <211> 51 <212> DNA <213> Homo sapiens <220> <221> misc_feature ≪ 222 > (26) <223> n is a, c, g, or t <400> 81 cttcatgtaa gctccaatga ctttcncaga gcctcccaca ttatagatga a 51 <210> 82 <211> 51 <212> DNA <213> Homo sapiens <220> <221> misc_feature ≪ 222 > (26) <223> n is a, c, g, or t <400> 82 aacccagatt ccagcaggac gggccncaaa gtctcgttac aagatgaagt g 51 <210> 83 <211> 51 <212> DNA <213> Homo sapiens <220> <221> misc_feature ≪ 222 > (26) <223> n is a, c, g, or t <400> 83 gcagtccaca gggaggagaa gttgtntcag catcagtaat gaatgcctta t 51 <210> 84 <211> 51 <212> DNA <213> Homo sapiens <220> <221> misc_feature ≪ 222 > (26) <223> n is a, c, g, or t <400> 84 agctgaccag agatggtacc gttgtntaga gattagcact ggaaagaaaa t 51 <210> 85 <211> 51 <212> DNA <213> Homo sapiens <220> <221> misc_feature ≪ 222 > (26) <223> n is a, c, g, or t <400> 85 gttagagcct gatagtgccg ttaagnggtc taagccacca gtttttctaa g 51 <210> 86 <211> 51 <212> DNA <213> Homo sapiens <220> <221> misc_feature ≪ 222 > (26) <223> n is a, c, g, or t <400> 86 ttaactttcc attaacgtgt ctcatnttcc tggaattcct atgtgagaat t 51 <210> 87 <211> 51 <212> DNA <213> Homo sapiens <220> <221> misc_feature ≪ 222 > (26) <223> n is a, c, g, or t <400> 87 gatttgttgt cattccttcc agtctngtct aaacatcatt tagtttggtg c 51 <210> 88 <211> 51 <212> DNA <213> Homo sapiens <220> <221> misc_feature ≪ 222 > (26) <223> n is a, c, g, or t <400> 88 cttttctttt ggatttgttg tcattncttc cagtctagtc taaacatcat t 51 <210> 89 <211> 51 <212> DNA <213> Homo sapiens <220> <221> misc_feature ≪ 222 > (26) <223> n is a, c, g, or t <400> 89 tactttcttt agaagaagat ataacncaga atcttgagaa tagtaaaaaa t 51 <210> 90 <211> 51 <212> DNA <213> Homo sapiens <220> <221> misc_feature ≪ 222 > (26) <223> n is a, c, g, or t <400> 90 caggttttat gccattgtgt aatatngtgg aaatgacatg gtccaggagt c 51 <210> 91 <211> 51 <212> DNA <213> Homo sapiens <220> <221> misc_feature ≪ 222 > (26) <223> n is a, c, g, or t <400> 91 tccgattgtt tccaatacct ggttcntttc cacaaatgtt cattagatta g 51 <210> 92 <211> 51 <212> DNA <213> Homo sapiens <220> <221> misc_feature ≪ 222 > (26) <223> n is a, c, g, or t <400> 92 catcttcttg atgaggtcta ctttantcac cctatttaac tttgcaactt g 51 <210> 93 <211> 51 <212> DNA <213> Homo sapiens <220> <221> misc_feature ≪ 222 > (26) <223> n is a, c, g, or t <400> 93 atggtcttca aagtcttcct tcatgnttct aacaataggt tgggttctgg a 51 <210> 94 <211> 51 <212> DNA <213> Homo sapiens <220> <221> misc_feature ≪ 222 > (26) <223> n is a, c, g, or t <400> 94 ccagcttctt atacgagata ctgaanaagc agcaactcag agaagtcatc t 51 <210> 95 <211> 51 <212> DNA <213> Homo sapiens <220> <221> misc_feature ≪ 222 > (26) <223> n is a, c, g, or t <400> 95 catctgagag tcttggtatt agatangatt attaaggcaa gtacatagag a 51 <210> 96 <211> 51 <212> DNA <213> Homo sapiens <220> <221> misc_feature ≪ 222 > (26) <223> n is a, c, g, or t <400> 96 aactgatttt ttagaaaaga ttgaangtga gaaaaaatga aataaaagaa t 51 <210> 97 <211> 51 <212> DNA <213> Homo sapiens <220> <221> misc_feature ≪ 222 > (26) <223> n is a, c, g, or t <400> 97 ctgctataag tgtaaagcat gccccncctg aatatgcaaa atatccttgg a 51 <210> 98 <211> 51 <212> DNA <213> Homo sapiens <220> <221> misc_feature ≪ 222 > (26) <223> n is a, c, g, or t <400> 98 gggacaggct aaagatggaa catggnatac ctaacaggac ttcagaagaa a 51 <210> 99 <211> 51 <212> DNA <213> Homo sapiens <220> <221> misc_feature ≪ 222 > (26) <223> n is a, c, g, or t <400> 99 attcatatgt aacacataga tgtatnacaa tagctcagga ttcattcgaa a 51 <210> 100 <211> 51 <212> DNA <213> Homo sapiens <220> <221> misc_feature ≪ 222 > (26) <223> n is a, c, g, or t <400> 100 ggaagaaggg ctgtgttctc aaactntgtt cctcagcccc tggagctaac a 51 <210> 101 <211> 51 <212> DNA <213> Homo sapiens <220> <221> misc_feature ≪ 222 > (26) <223> n is a, c, g, or t <400> 101 agaaagctga catcaagata aaaccngcct tcacttcccc atgctggacc t 51 <210> 102 <211> 51 <212> DNA <213> Homo sapiens <220> <221> misc_feature ≪ 222 > (26) <223> n is a, c, g, or t <400> 102 ctccaaatat ggttattatt tttaangttt agcatcacca gaatccatag a 51 <210> 103 <211> 51 <212> DNA <213> Homo sapiens <220> <221> misc_feature ≪ 222 > (26) <223> n is a, c, g, or t <400> 103 ccttgcatcc cctgaatcac ttactnttat tgtgtacatt ttaaaacata g 51 <210> 104 <211> 51 <212> DNA <213> Homo sapiens <220> <221> misc_feature ≪ 222 > (26) <223> n is a, c, g, or t <400> 104 ttactgcttc cttttcataa gcaaancatc atgtggctaa gcagctctct a 51 <210> 105 <211> 51 <212> DNA <213> Homo sapiens <220> <221> misc_feature ≪ 222 > (26) <223> n is a, c, g, or t <400> 105 tttgtggaga caccagagct attgcnggtt tcactgagtc tctggaagat t 51 <210> 106 <211> 51 <212> DNA <213> Homo sapiens <220> <221> misc_feature ≪ 222 > (26) <223> n is a, c, g, or t <400> 106 ccagtggctg ggcatgatta cacgangagg attctaaatc ctgtttcatg t 51 <210> 107 <211> 51 <212> DNA <213> Homo sapiens <220> <221> misc_feature ≪ 222 > (26) <223> n is a, c, g, or t <400> 107 aaggtcatat taacttggat tcaaantctg ggtgtgacac ttacgagctg t 51 <210> 108 <211> 51 <212> DNA <213> Homo sapiens <220> <221> misc_feature ≪ 222 > (26) <223> n is a, c, g, or t <400> 108 ataagggaac tctagagaac aactcngtcc aatgctttgg gagagatgga g 51 <210> 109 <211> 51 <212> DNA <213> Homo sapiens <220> <221> misc_feature ≪ 222 > (26) <223> n is a, c, g, or t <400> 109 aatattgaac tagcataaat atttgntttg aatgatcttt catcttccta a 51 <210> 110 <211> 51 <212> DNA <213> Homo sapiens <220> <221> misc_feature ≪ 222 > (26) <223> n is a, c, g, or t <400> 110 ccacacccag taatgttgta tgttangttt tactctcttg tgtggtgtta t 51 <210> 111 <211> 51 <212> DNA <213> Homo sapiens <220> <221> misc_feature ≪ 222 > (26) <223> n is a, c, g, or t <400> 111 taataaaaga catagaagat ctgaanaaat ggagagacag ttcatactca g 51 <210> 112 <211> 51 <212> DNA <213> Homo sapiens <220> <221> misc_feature ≪ 222 > (26) <223> n is a, c, g, or t <400> 112 tttttgtagg ggagagagaa gatcangtat ttagaataaa agcctaggct a 51 <210> 113 <211> 51 <212> DNA <213> Homo sapiens <220> <221> misc_feature ≪ 222 > (26) <223> n is a, c, g, or t <400> 113 ttcctttcag ttgggaagac ctaccngaat tatttttcct gccactttga c 51 <210> 114 <211> 51 <212> DNA <213> Homo sapiens <220> <221> misc_feature ≪ 222 > (26) <223> n is a, c, g, or t <400> 114 ggagtcagag tgggtcagag agaagncact ttgagcaacc aaataaacac a 51 <210> 115 <211> 51 <212> DNA <213> Homo sapiens <220> <221> misc_feature ≪ 222 > (26) <223> n is a, c, g, or t <400> 115 aaaacaacac tatggaggca gcagtnatac agtggcgtga ctgctgctgc a 51
Claims (15)
At least one polynucleotide selected from the group consisting of a second polynucleotide having 10 or more consecutive nucleotide sequences including a 26th single nucleotide polymorphic site of the nucleotide sequence of SEQ ID NO: 2 and a complementary polynucleotide thereof A second marker polynucleotide comprising;
A third polynucleotide having 10 or more consecutive nucleotide sequences including a 26th single nucleotide polymorphic site of the nucleotide sequence of SEQ ID NO: 3 and a complementary polynucleotide thereof, and at least one polynucleotide selected from the group consisting of A third marker polynucleotide;
At least one polynucleotide selected from the group consisting of a fourth polynucleotide having 10 or more consecutive nucleotide sequences including a 26 th single nucleotide polymorphic site of the nucleotide sequence of SEQ ID NO: 4 and a complementary polynucleotide thereof A fourth marker polynucleotide comprising;
At least one polynucleotide selected from the group consisting of a fifth polynucleotide having at least 10 consecutive nucleotide sequences including a single nucleotide polymorphic site of the nucleotide sequence of SEQ ID NO: 5 and a complementary polynucleotide thereof A fifth marker polynucleotide;
At least one polynucleotide selected from the group consisting of a sixth polynucleotide having 10 or more consecutive nucleotide sequences including a 26th single nucleotide polymorphic site of the nucleotide sequence of SEQ ID NO: 6 and a complementary polynucleotide thereof A sixth marker polynucleotide;
At least one polynucleotide selected from the group consisting of a seventh polynucleotide having at least 10 consecutive nucleotide sequences including a single nucleotide polymorphic site of the nucleotide sequence of SEQ ID NO: 7 and a complementary polynucleotide thereof A seventh marker polynucleotide comprising;
An eighth polynucleotide having 10 or more consecutive nucleotide sequences comprising a 26th single nucleotide polymorphic site of the nucleotide sequence of SEQ ID NO: 8 and at least one polynucleotide selected from the group consisting of complementary polynucleotides thereof An eighth marker polynucleotide;
At least one polynucleotide selected from the group consisting of a ninth polynucleotide having at least 10 consecutive nucleotide sequences including a single nucleotide polymorphic site of the nucleotide sequence of SEQ ID NO: 9 and a complementary polynucleotide thereof A ninth marker polynucleotide;
A tenth polynucleotide having 10 or more consecutive nucleotide sequences comprising a 26th single nucleotide polymorphic site of the nucleotide sequence of SEQ ID NO: 10 and at least one polynucleotide selected from the group consisting of complementary polynucleotides thereof A tenth marker polynucleotide comprising;
At least one polynucleotide selected from the group consisting of an eleventh polynucleotide having 10 or more consecutive nucleotide sequences including a 26 th single nucleotide polymorphic site of the nucleotide sequence of SEQ ID NO: 11 and a complementary polynucleotide thereof An eleventh marker polynucleotide;
At least one polynucleotide selected from the group consisting of a twelfth polynucleotide having 10 or more consecutive nucleotide sequences including a 26th single nucleotide polymorphic site of the nucleotide sequence of SEQ ID NO: 12 and a complementary polynucleotide thereof A twelfth marker polynucleotide;
A thirteenth polynucleotide having 10 or more consecutive nucleotide sequences including a 26 th single nucleotide polymorphic site of the nucleotide sequence of SEQ ID NO: 13 and at least one polynucleotide selected from the group consisting of complementary polynucleotides thereof A thirteen marker polynucleotide;
One or more polynucleotides selected from the group consisting of a 14th polynucleotide having 10 or more consecutive nucleotide sequences including a 26th single nucleotide polymorphic site of the nucleotide sequence of SEQ ID NO: 14 and a complementary polynucleotide thereof A 14th marker polynucleotide comprising;
At least one polynucleotide selected from the group consisting of a 15th polynucleotide having 10 or more consecutive nucleotide sequences including a 26th single nucleotide polymorphic site of the nucleotide sequence of SEQ ID NO: 15 and a complementary polynucleotide thereof A 15 marker polynucleotide;
At least one polynucleotide selected from the group consisting of a 16th polynucleotide having 10 or more consecutive nucleotide sequences including a 26th single nucleotide polymorphic site of the nucleotide sequence of SEQ ID NO: 16 and a complementary polynucleotide thereof A 16th marker polynucleotide comprising;
A seventeenth polynucleotide having 10 or more consecutive nucleotide sequences including a 26th single nucleotide polymorphic site of the nucleotide sequence of SEQ ID NO: 17, and a complementary polynucleotide thereof, and at least one polynucleotide selected from the group consisting of A seventeenth marker polynucleotide comprising;
At least one polynucleotide selected from the group consisting of an 18th polynucleotide having 10 or more consecutive nucleotide sequences including a 26th single nucleotide polymorphic site of the nucleotide sequence of SEQ ID NO: 18 and a complementary polynucleotide thereof An 18th marker polynucleotide;
One or more polynucleotides selected from the group consisting of a 19th polynucleotide having 10 or more consecutive nucleotide sequences including a 26th single nucleotide polymorphic site of the nucleotide sequence of SEQ ID NO: 19 and a complementary polynucleotide thereof 19th marker polynucleotide;
At least one polynucleotide selected from the group consisting of a 20th polynucleotide having 10 or more consecutive nucleotide sequences including a 26th single nucleotide polymorphic site of the nucleotide sequence of SEQ ID NO: 20 and a complementary polynucleotide thereof A 20 marker polynucleotide comprising;
A polynucleotide having a nucleotide sequence of SEQ ID NO: 21 and a twenty-first polynucleotide having at least 10 consecutive nucleotide sequences including a single nucleotide polymorphic site of the nucleotide sequence of SEQ ID NO: 21 and at least one polynucleotide selected from the group consisting of complementary polynucleotides thereof A 21st marker polynucleotide;
At least one polynucleotide selected from the group consisting of a 22nd polynucleotide having 10 or more consecutive nucleotide sequences including a 26th single nucleotide polymorphic site of the nucleotide sequence of SEQ ID NO: 22 and a complementary polynucleotide thereof A < / RTI > 22 marker polynucleotide;
A 23rd polynucleotide having 10 or more consecutive nucleotide sequences including a 26th single nucleotide polymorphic site of the nucleotide sequence of SEQ ID NO: 23, and a complementary polynucleotide thereof, and at least one polynucleotide selected from the group consisting of A 23rd marker polynucleotide;
A 24 th polynucleotide having 10 or more consecutive nucleotide sequences including a 26 th single nucleotide polymorphic site of the nucleotide sequence of SEQ ID NO: 24, and a complementary polynucleotide thereof, and at least one polynucleotide selected from the group consisting of A 24th marker polynucleotide;
A 25th polynucleotide having 10 or more consecutive nucleotide sequences including a 26th single nucleotide polymorphic site of the nucleotide sequence of SEQ ID NO: 25, and at least one polynucleotide selected from the group consisting of complementary polynucleotides thereof A 25 marker polynucleotide comprising: < RTI ID = 0.0 >
A 26th polynucleotide having 10 or more consecutive nucleotide sequences including a 26th single nucleotide polymorphic site of the nucleotide sequence of SEQ ID NO: 26, and a complementary polynucleotide thereof, and at least one polynucleotide selected from the group consisting of A 26 marker polynucleotide;
A 27th polynucleotide having 10 or more consecutive nucleotide sequences including a 26th single nucleotide polymorphic site of the nucleotide sequence of SEQ ID NO: 27, and a complementary polynucleotide thereof, and at least one polynucleotide selected from the group consisting of 27 marker polynucleotides;
A 28th polynucleotide having 10 or more consecutive nucleotide sequences comprising a 26th single nucleotide polymorphic site of the nucleotide sequence of SEQ ID NO: 28 and at least one polynucleotide selected from the group consisting of complementary polynucleotides thereof A 28 marker polynucleotide;
One or more polynucleotides selected from the group consisting of a 29th polynucleotide having 10 or more consecutive nucleotide sequences including a 26th single nucleotide polymorphic site of the nucleotide sequence of SEQ ID NO: 29 and a complementary polynucleotide thereof 29 marker polynucleotides;
At least one polynucleotide selected from the group consisting of a 30th polynucleotide having 10 or more consecutive nucleotide sequences including a 26th single nucleotide polymorphic site of the nucleotide sequence of SEQ ID NO: 30 and a complementary polynucleotide thereof A 30 th marker polynucleotide;
A 31st polynucleotide having 10 or more consecutive nucleotide sequences comprising a 26th single nucleotide polymorphic site of the nucleotide sequence of SEQ ID NO: 31, and a complementary polynucleotide thereof, and at least one polynucleotide selected from the group consisting of A 31st marker polynucleotide;
A 32nd polynucleotide having 10 or more consecutive nucleotide sequences comprising a 26th single nucleotide polymorphic site of the nucleotide sequence of SEQ ID NO: 32, and a complementary polynucleotide thereof, and at least one polynucleotide selected from the group consisting of A 32 th marker polynucleotide;
At least one polynucleotide selected from the group consisting of a 33 polynucleotide having 10 or more consecutive nucleotide sequences including a 26-th single nucleotide polymorphic site of the nucleotide sequence of SEQ ID NO: 33 and a complementary polynucleotide thereof 33 marker polynucleotides;
A 34th polynucleotide having 10 or more consecutive nucleotide sequences including a 26th single nucleotide polymorphic site of the nucleotide sequence of SEQ ID NO: 34 and at least one polynucleotide selected from the group consisting of complementary polynucleotides thereof 34 marker polynucleotides;
35 th polynucleotide having 10 or more consecutive nucleotide sequences including a 26 th single nucleotide polymorphic site of the nucleotide sequence of SEQ ID NO: 35 and at least one polynucleotide selected from the group consisting of complementary polynucleotides thereof 35 marker polynucleotides;
At least one polynucleotide selected from the group consisting of a 36th polynucleotide having 10 or more consecutive nucleotide sequences including a 26th single nucleotide polymorphic site of the nucleotide sequence of SEQ ID NO: 36 and a complementary polynucleotide thereof 36 marker polynucleotides;
A 37th polynucleotide having 10 or more consecutive nucleotide sequences including a 26th single nucleotide polymorphic site of the nucleotide sequence of SEQ ID NO: 37, and a complementary polynucleotide thereof, and at least one polynucleotide selected from the group consisting of 37 marker polynucleotides;
At least one polynucleotide selected from the group consisting of a 38 polynucleotide having 10 or more consecutive nucleotide sequences including a 26 th single nucleotide polymorphic site of the nucleotide sequence of SEQ ID NO: 38 and a complementary polynucleotide thereof A < / RTI > 38 marker polynucleotide;
39 polynucleotides having 10 or more consecutive nucleotide sequences comprising a 26 < th > first single nucleotide polymorphic site of the nucleotide sequence of SEQ ID NO: 39 and at least one polynucleotide selected from the group consisting of complementary polynucleotides thereof A < / RTI > 39 marker polynucleotide;
One or more polynucleotides selected from the group consisting of a 40 polynucleotide having 10 or more consecutive nucleotide sequences including a 26 th single nucleotide polymorphic site of the nucleotide sequence of SEQ ID NO: 40 and a complementary polynucleotide thereof A < / RTI > 40 marker polynucleotide;
At least one polynucleotide selected from the group consisting of a 41st polynucleotide having 10 or more consecutive nucleotide sequences including a 26th single nucleotide polymorphic site of the nucleotide sequence of SEQ ID NO: 41 and a complementary polynucleotide thereof A 31st marker polynucleotide;
At least one polynucleotide selected from the group consisting of a 42 polynucleotide having 10 or more consecutive nucleotide sequences including a 26 th single nucleotide polymorphic site of the nucleotide sequence of SEQ ID NO: 42 and a complementary polynucleotide thereof A 32 th marker polynucleotide;
A polynucleotide selected from the group consisting of a 43 polynucleotide having 10 or more consecutive nucleotide sequences including a single nucleotide polymorphic site of the nucleotide sequence of SEQ ID NO: 43 and a complementary polynucleotide thereof; 33 marker polynucleotides;
A 44th polynucleotide having 10 or more consecutive nucleotide sequences including a 26th single nucleotide polymorphic site of the nucleotide sequence of SEQ ID NO: 44, and a complementary polynucleotide thereof, and at least one polynucleotide selected from the group consisting of 34 marker polynucleotides;
A 45th polynucleotide having 10 or more consecutive nucleotide sequences including a 26th single nucleotide polymorphic site of the nucleotide sequence of SEQ ID NO: 45 and a complementary polynucleotide thereof; and at least one polynucleotide selected from the group consisting of 35 marker polynucleotides;
One or more polynucleotides selected from the group consisting of a 46th polynucleotide having 10 or more consecutive nucleotide sequences including a 26th single nucleotide polymorphic site of the nucleotide sequence of SEQ ID NO: 46 and a complementary polynucleotide thereof 36 marker polynucleotides;
A 47th polynucleotide having 10 or more consecutive nucleotide sequences comprising a 26th single nucleotide polymorphic site of the nucleotide sequence of SEQ ID NO: 47, and a complementary polynucleotide thereof, and at least one polynucleotide selected from the group consisting of 37 marker polynucleotides;
One or more polynucleotides selected from the group consisting of a 48 polynucleotide having 10 or more consecutive nucleotide sequences including a 26 th single nucleotide polymorphic site of the nucleotide sequence of SEQ ID NO: 48 and a complementary polynucleotide thereof A < / RTI > 38 marker polynucleotide;
One or more polynucleotides selected from the group consisting of a 49th polynucleotide having 10 or more consecutive nucleotide sequences including a 26th single nucleotide polymorphic site of the nucleotide sequence of SEQ ID NO: 49 and a complementary polynucleotide thereof A < / RTI > 39 marker polynucleotide;
One or more polynucleotides selected from the group consisting of a 50 polynucleotide having 10 or more consecutive nucleotide sequences including a 26 th single nucleotide polymorphic site of the nucleotide sequence of SEQ ID NO: 50 and a complementary polynucleotide thereof A < / RTI > 40 marker polynucleotide;
A polynucleotide of the 51st polynucleotide having 10 or more consecutive nucleotide sequences including a 26th single nucleotide polymorphic site of the nucleotide sequence of SEQ ID NO: 51 and a complementary polynucleotide thereof; A 51st marker polynucleotide;
52 polynucleotides having at least 10 consecutive nucleotide sequences comprising the 26 th single nucleotide polymorphic site of the nucleotide sequence of SEQ ID NO: 52 and complementary polynucleotides thereof, and at least one polynucleotide selected from the group consisting of complementary polynucleotides thereof A < / RTI > 52 marker polynucleotide;
53 polynucleotides having 10 or more consecutive nucleotide sequences comprising a 26-th single nucleotide polymorphic site of the nucleotide sequence of SEQ ID NO: 53, and complementary polynucleotides thereof, and at least one polynucleotide selected from the group consisting of A < / RTI > 53 marker polynucleotide; And
54 polynucleotides having 10 or more consecutive nucleotide sequences comprising a 26-th single nucleotide polymorphic site of the nucleotide sequence of SEQ ID NO: 54 and at least one polynucleotide selected from the group consisting of complementary polynucleotides thereof 54. A composition for identifying exercise performance, comprising: a cardiovascular endurance;
Determining the presence or absence of at least one single base polymorphism of the first marker polynucleotide to the 54th marker polynucleotide in the nucleic acid from the resulting hybridization product to provide a SNP profile of the nucleic acid; 6. A method of obtaining information required for confirmation, the exercise performance being cardiopulmonary endurance.
Comparing the SNP profile of the nucleic acid of the subject with the SNP profile of the control subject.
(major / minor)
.
Determining the presence or absence of at least one single base polymorphism of the first marker polynucleotide to the 54th marker polynucleotide in the nucleic acid from the resultant hybridization product to provide the SNP profile of the nucleic acid, The presence or absence of a minor allele or major allele of the SNP shown in Table 16;
(major / minor)
If the SNP profile has at least one allele associated with exercise performance among the minor allele and major allele of the SNPs shown in Table 16, the subject may have a higher or higher exercise performance ability than a non-athlete or other athlete And determining that the possibility of motion is high, the method being characterized in that the exercise performance is cardiopulmonary endurance.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020160013528A KR101908594B1 (en) | 2016-02-03 | 2016-02-03 | Composition, kit or microarray for indentifying athletic performance comprising marker polynucleotide, and method for obtaining information for indentifying athletic performance using the same |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020160013528A KR101908594B1 (en) | 2016-02-03 | 2016-02-03 | Composition, kit or microarray for indentifying athletic performance comprising marker polynucleotide, and method for obtaining information for indentifying athletic performance using the same |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020180025910A Division KR101908596B1 (en) | 2018-03-05 | 2018-03-05 | Composition, kit or microarray for indentifying athletic performance, maximum muscular strength, comprising marker polynucleotide, and method for obtaining information for indentifying athletic performance, maximum muscular strength using the same |
| KR1020180025911A Division KR101908597B1 (en) | 2018-03-05 | 2018-03-05 | Composition, kit or microarray for indentifying athletic performance, speed comprising marker polynucleotide, and method for obtaining information for indentifying athletic performance, speed using the same |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20170092320A KR20170092320A (en) | 2017-08-11 |
| KR101908594B1 true KR101908594B1 (en) | 2018-12-19 |
Family
ID=59651336
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020160013528A KR101908594B1 (en) | 2016-02-03 | 2016-02-03 | Composition, kit or microarray for indentifying athletic performance comprising marker polynucleotide, and method for obtaining information for indentifying athletic performance using the same |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR101908594B1 (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010028256A2 (en) * | 2008-09-05 | 2010-03-11 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Predictive biomarkers |
| US20130130918A1 (en) * | 2010-02-05 | 2013-05-23 | Genetics Investment Pty. Ltd. | Exercise genotyping |
| KR101545258B1 (en) | 2014-08-14 | 2015-08-24 | 주식회사 대웅제약 | Biomarker for predicting of sensitivity to exercise |
-
2016
- 2016-02-03 KR KR1020160013528A patent/KR101908594B1/en active IP Right Grant
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010028256A2 (en) * | 2008-09-05 | 2010-03-11 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Predictive biomarkers |
| US20130130918A1 (en) * | 2010-02-05 | 2013-05-23 | Genetics Investment Pty. Ltd. | Exercise genotyping |
| KR101545258B1 (en) | 2014-08-14 | 2015-08-24 | 주식회사 대웅제약 | Biomarker for predicting of sensitivity to exercise |
Non-Patent Citations (3)
| Title |
|---|
| "한국형 운동능력별 엘리트 선수의 우수 체력 SNP 진단 Chip 개발을 위한 Pilot study" 한국체육과학연구원 연구보고서 (2014. 3.) |
| Celluar and Molecular Exercise Phsyology Vol.1(1), e1. doi:10.7457/cmep.vlil.e1. (2012. 10. 19.) |
| Medicine & Science in Sports & Exercise, DOI:10.1249/MSS.ob013e3181844179. (2008. 6.) |
Also Published As
| Publication number | Publication date |
|---|---|
| KR20170092320A (en) | 2017-08-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101583546B1 (en) | Method for prediction of reactivity to sorafenib treatment Using gene polymorphism | |
| US20150159220A1 (en) | Methods for predicting and detecting cancer risk | |
| AU2012212499A1 (en) | Method for discovering pharmacogenomic biomarkers | |
| WO2012099397A2 (en) | Method for determining the single nucleotide polymorphism of target genes using a real-time polymerase chain reaction, and kit for determining the single nucleotide polymorphism of target genes using same | |
| KR101312480B1 (en) | Novel snp marker for discriminating number of rib of pig and use thereof | |
| CN110734974B (en) | SNP locus combination and detection primer for cancer chemotherapy drugs | |
| KR101908596B1 (en) | Composition, kit or microarray for indentifying athletic performance, maximum muscular strength, comprising marker polynucleotide, and method for obtaining information for indentifying athletic performance, maximum muscular strength using the same | |
| KR101908594B1 (en) | Composition, kit or microarray for indentifying athletic performance comprising marker polynucleotide, and method for obtaining information for indentifying athletic performance using the same | |
| KR101908597B1 (en) | Composition, kit or microarray for indentifying athletic performance, speed comprising marker polynucleotide, and method for obtaining information for indentifying athletic performance, speed using the same | |
| KR101249635B1 (en) | Novel EGR2 SNPs Related to Bipolar Disorder, Microarrays and Kits Comprising them for Diagnosing Bipolar Disorder | |
| EP1262565A2 (en) | Genetic polymorphisms in the human neurokinin 1 receptor gene and their uses in diagnosis and treatment of diseases | |
| KR102173458B1 (en) | Single nucleotide polymorphism marker composition for prediction of body condition score of domestic cow and uses thereof | |
| US20050244830A1 (en) | Quantitative multiplex amplification on a genomic scale, and applications for detecting genomic rearrangements | |
| US9139881B2 (en) | Method for assessing breast cancer susceptibility | |
| KR101731619B1 (en) | Polynucleotide marker composition for identifying father and daughter and its use | |
| KR20210154527A (en) | Markers for Predicting side effects of statin | |
| Amr et al. | Targeted hybrid capture for inherited disease panels | |
| KR101663171B1 (en) | Biomarkers indicative of Down Syndrom and Their uses | |
| RU2749465C1 (en) | Method for determining genetic markers for assessing polygenic risk of breast cancer (hormone-negative and hormone-positive subtypes) | |
| LU102676B1 (en) | A Biomarker for Severe Asthma and Application Thereof | |
| CN115725745B (en) | SNP molecular marker related to sheep multi-thoracic vertebrae and amplification primer set and application | |
| CN113604602B (en) | STR molecular marker of nematophagous fungi Arthrobotrya oligospora | |
| US20230136481A1 (en) | Method for assessing risk of developing hepatocellular carcinoma from non-alcoholic steatohepatitis | |
| KR20230101467A (en) | Single-nucleotide polymorphic biomarkers for predicting obesity risk according to eating habits and use thereof | |
| KR20230018185A (en) | InDel markers for discriminating malting barley varieties and uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| E902 | Notification of reason for refusal | ||
| E902 | Notification of reason for refusal | ||
| A107 | Divisional application of patent | ||
| GRNT | Written decision to grant |